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Purpose
The purpose of this study is to explore the association between gender and racial lines in
the conversion and sustainment of normal sinus rhythm (NSR) from paroxysmal atrial fibrillation
(PAF) and persistent atrial fibrillation using the anti-arrhythmic drugs (AADs) sotalol and
dofetilide.
Methods
A secondary data analysis was performed to assess the relationships of the independent
and dependent variables listed above. Using SPSS v. 24 descriptive statistics were obtained and
initially evaluated for accuracy with histograms. A cross-tabulation frequency table was
produced to determine the number of variables that fell into each dependent category. Following
this, the frequencies were checked to ensure that the assumption for chi-square had been met. As
the chi-square assumption had not been met with respect to race, this variable was discarded for
future data analysis. Fisher’s exact test was used to determine statistical significance of any
association between independent and dependent variables. Human Subjects Review Board

approval was obtained at Western Michigan University and the participating institution where
the study was performed.
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CHAPTER I
INTRODUCTION
Minorities and women are largely underrepresented in clinical trials (Perez-Stable, 2018).
A study performed by the Food and Drug Administration (FDA) Office of Women’s Health
(2011a) found that African-Americans made up 12% of the United States (U.S.) population but
only 5% of clinical trial participants and Hispanics made up 16% of the U.S. population but only
1% of clinical trial participants. Geller, Koch, Pellettieri, and Carnes (2011) analyzed nine
medical journals to evaluate the inclusion and analysis of gender in the results of federally
funded randomized controlled trials (RCT) in 9 major medical journals in 2009. The clinical
trials evaluated were focused in the areas of internal medicine, oncology, cardiology, infectious
disease, obstetrics, and gynecology. The journals were selected based on their impact factor in
2003 which is a rating frequency with which articles in the journal are cited in a given year
(Geller, Koch, Pellettieri, & Carnes, 2011). The journals included in the study were the New
England Journal of Medicine, Journal of the American Medical Association, Annals of Internal
Medicine, American Journal of Medicine, Journal of Clinical Oncology, Circulation, Clinical
Infectious Disease, Obstetrics and Gynecology, and the American Journal of Obstetrics and
Gynecology (Geller et al., 2011). The study found that the average participation of female
enrollment in the RCTs that were not gender based was 37%. It also found that 64% of the
studies did not report study results by gender (Geller et al., 2011).
Race, ethnicity, and gender play integral roles in inter-individual differences in drug
exposure, efficacy, and safety (Ramamoorthy, Pacanowski, Bull & Zang, 2014) and there are
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well-established differences in the incidence of disease between males and females and among
racial and ethnic groups (Food and Drug Administration Office of Women’s Health [FDA],
2011a). These differences highlight the importance and the need for diversification of gender,
race, and ethnicity in clinical trials related to medications and treatments. This is exemplified in
well documented health disparities. According to the National Institute of Health (2016), “health
disparities are differences that exist among specific population groups in the United States in the
attainment of full health potential that can be measured by differences in incidence, prevalence,
mortality, burden of disease, and other adverse health conditions.” Minorities and females are
disproportionately affected by many disease processes but are underrepresented in the very
clinical trials to combat these diseases. For example, according to a comparison done by the
FDA in 2005, there were 850,000 new cases of DM between 1998 and 2001. Of those, 37%
were black, 24% were white, 36% were Hispanic, 1% were Asian, and 2.1% were classified as
other. In clinical trials related to safety, efficacy, exercise, dietary intervention, etc., during
approximately the same time period, there was a total of 7,979 participants enrolled. Of those,
85% were white, 10% were black, 4% were Hispanic, 1% were Asian, and 0% were classified as
other (FDA, 2011a). Coronary artery disease (CAD) is the leading cause of death in women in
the U.S. resulting in 299,578 deaths in 2017 or 1 in every 5 female deaths. Coronary artery
disease is also prevalent in men accounting for 321,000 deaths in 2013 or 1 in every 4 male
deaths (Centers for Disease Control and Prevention [CDC], 2019b). Despite the similar
prevalence and mortality cause by CAD between males and females, females are less likely to be
enrolled in clinical trials for cardiovascular disease (CVD) (Ramasubbu, Gurm, & Litaker,
2001). Barriers facing females and non-whites to involvement in clinical trials are manifold. As
2

it pertains to African-Americans, a lack of awareness about trials, economic factors,
communication issues, and mistrust in the medical industry are the most common reasons for
lack of participation in clinical trials (Harris, Gorelick, Samuels, & Bempong, 1996). In the case
of women, insurance status, inconvenience, availability of transportation, and distance to study
site have been cited as reasons for reduced participation (FDA, 2011a).
The FDA has approved many drugs which were deemed safe and effective based on
clinical trials that were overwhelmingly representative of white males only to find that months
to even years after marketing and use by consumers, some of these drugs were either
ineffective or unsafe for non-whites and women (Perez-Stable, 2018; Weyant, 2017). As many
of the adverse reactions or variability in a drugs lifecycle are found after the drug has been
marketed, reporting of these events becomes paramount to public health and safety (Weyant,
2017). Since 2004, the FDA has provided the FDA’s Adverse Event Reporting System
(FAERS) where industry professionals such as health care providers and pharmacists,
consumers, and citizens can report adverse events related to drugs (Weyant, 2017). Once an
event is reported to the system it is reviewed by clinicians in the Center for Drug Evaluation
and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) (Weyant,
2017). Concerning reviews may be escalated to investigations by the FDA which may
ultimately lead to regulatory action in the form of labeling and use restrictions, post-market
prescribing recommendations, individualization of labeling for specific subpopulations, blackbox warnings, or the reversal of FDA approval (Ramamoorthy, 2014; Weyant, 2017). A blackbox warning is the strongest medication related safety concern that the FDA can issue for a
prescription drug (Cheng, Guglielmo, & Maselli, 2010). These warnings are reserved for special
3

problems that may lead to serious injury or death caused by a medication (Beach, Faich,
Bormel, & Sasinowski, 1998). For medications with black-box warnings there is a prominently
displayed box surrounding text on the promotional material and package inserts that specifically
describes the potential adverse event(s) in an effort to bring attention to the prescribing
individual, consumer, and the public (Beach et al., 1998; Weyant, 2017).
According to Wagner et al. (2005), an official list of drugs with black-box warnings does
not exist however Weyant (2017) estimates that there are approximately 600 drugs that on the
market with black-box warnings. Two pertinent examples with adverse effects on specific
subpopulations underrepresented in clinical trials are clopidogrel and salmeterol.
Clopidogrel is an anti-platelet drug often used for patients with atherosclerotic vascular
disease and routinely given after a patient has had a myocardial infarction (MI) and percutaneous
coronary intervention (PCI) to prevent thromboembolic events associated with enhanced platelet
activity (Perez-Stable, 2018; Wagner, 2005). The black-box warning from Bristol-MeyersSquibb (2019) states:
The effectiveness of this drug depends on conversion to an active metabolite by
cytochrome P450 (CYP) system, principally CYP2C19. Consider use of another platelet
PY2 inhibitor in patients identified as CYP2C19 poor-metabolizers (p. 2).
A study by Bhopalwala, Hong, Khan, Valentin, and Badawi (2015) revealed that 25-50% of
people with East Asian and South Asian backgrounds are CYP2C19 poor-metabolizers which is
associated with decreased rates of clopidogrel activation rendering them at increased risk for
thrombotic events.

4

Salmeterol is a long-acting β2 adrenergic receptor agonist (LABA) used to maintain
symptoms of asthma and chronic obstructive pulmonary disease (COPD) (GlaxoSmithKline,
2020). Salmeterol may also be used as a combined medication with inhaled corticosteroids
(ICS) (GlaxoSmithKline, 2020). The black-box warning from GlaxoSmithKline (2020) states:
Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, the active ingredient
in SEREVENT DISKUS, as a monotherapy (without inhaled corticosteroids [(ICS])
increase the risk of asthma-related death. Data from a large placebo-controlled U.S. trial
that compared the safety of salmeterol with placebo added to usual asthma therapy
showed an increase in asthma-related deaths in subjects receiving salmeterol (13 deaths
out of 13,176 subjects treated for 28 weeks on salmeterol versus 3 deaths out of 13,179
subjects on placebo (p. 2).
The Salmeterol Multi-Center Asthma Research Trial (SMART) was a randomized, double-blind,
placebo-controlled observational surveillance study conducted at 6136 U.S. sites between 1996
and 2003 (GlaxoSmithKline, 2020; Nelson, Weiss, Bleecker, Yancy, & Dorinsky, 2006). The
purpose of the study was to compare respiratory and asthma-related outcomes in subjects
receiving the usual asthma pharmacotherapy with the addition of placebo versus the usual
asthma pharmacotherapy with the addition of salmeterol. The study was prematurely terminated
due to an interim analysis showing that patients receiving salmeterol were at increased risk of
sudden death compared to those who received placebo (GlaxoSmithKline, 2020; Nelson et al.,
2006). In comparison to the total population and Caucasian population in the study receiving
salmeterol, there were 8 deaths per 10,000 patients in the total population, 6 deaths per 10,000
5

patients in Caucasian population, and 27 deaths per 10,000 patients in the African-American
population (GlaxoSmithKline, 2020, p. 2). These findings further highlight the need for
increasing diversity in clinical trials.
This chapter provided an introduction and shall go forward to provide the background
of the study and a brief overview of the theoretical framework. It will then describe the
statement of the problem, purpose of the study, research questions, and significance of the
study. Lastly, it will conclude with definitions of terms, assumptions, limitations,
delimitations, and a chapter conclusion.
1.1 Background
The use of a new drug and/or treatment should be based on the results of well designed,
unbiased controlled double-blind clinical trials that include people representing the full range of
the population most likely to use the drug once it is marketed (King, 2002). According to
Knepper and McLeod (2018), the number of countries contributing data to clinical trials for
approval of drugs nearly doubled from 32 to 57 between 1997 and 2014, however this increase
has not correlated with an increase in the racial diversity of people enrolled in studies. In 1997
according to data from the FDA, 92% of participants in clinical trials were white and in 2014
nearly 86% were white (Knepper & McLeod, 2018). In an effort to determine which populations
were used by the FDA to provide safety and efficacy information Knepper and McLeod (2018)
reviewed the approvals of new drugs made by the agency over 5 points in time (1997, 2004,
2009, 2012, and 2014) from 1997 to 2014. The focus of the probe was on treatments approved
for heart disease, cancer, and disorders of the central nervous system (CNS) as conditions of
6

these systems are common globally. For each drug approval the race (White, Black, Asian,
Other (any person not described as White, Black, or Asian)) of people enrolled and the country
in which the people were from were documented. During this time period, 81 drugs were
approved based on clinical trials which included nearly 150,000 people from 29 countries
including the U.S., Africa, Europe, Asia-Pacific, and Latin America. Despite the growing
number of participating countries in clinical trials, over the five points of time, there was no
appreciable change in racial enrollment (Knepper & McLeod, 2018). Ethnic minorities
continued to be underrepresented while the participating majority remained white. The median
percentage of African and African American participants per trial ranged from 1.8% to 3.5%,
Asian participants per trial ranged from 0% to 7%, and for those classified as other, participation
was 1.4% to 3.4%. At each point in time the vast majority of people enrolled in these clinical
trials were white (Knepper & McLeod, 2018).
Among variables such as genetics, age, diet, comorbidities, and concomitant use of other
medications, race is an important factor that may affect a patient’s response to new medications
(King, 2002). It is imperative to consider race during drug development due to factors that can
affect the pharmacokinetics, or the movement of drugs within the body and what the body does
to the drug and pharmacodynamics, or the biochemical, physiologic, and molecular effects of
drugs on the body that differ among races (Merck, 2019; Ramamoorthy et al., 2014).
According to Ramamoorthy et al. (2014), approximately 1/5 of new drugs approved from 2008
to 2014 demonstrated differences in exposure, response, efficacy, and safety in whites when
compared to those of other racial and ethnic lines.
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One of the most prevalent causes of the differences in exposure, response, efficacy, and
safety of drugs across racial and gender lines is related to differences in the body’s
metabolism. The liver’s cytochrome CYP450 family of enzymes is designed to metabolize
drugs and detoxify the body of foreign chemicals or xenobiotics (Alessandrini, Asfaha,
Dogden, Warnich, & Pepper, 2013). There are multiple CYP450 subtypes responsible for the
metabolism of specific medications and foreign substances however a complete classification
of each subtype would be beyond the scope of this paper. In relating the differences in drug
responses relevant to this paper at the interracial level, those subtypes will be discussed.
Although drug metabolism occurs in the intestinal walls, lungs, kidneys, and plasma,
the liver is the primary site (Eastabrook, 2003; McDonnell & Dang, 2013). Not all drugs have
CYP450 activity however drugs with CYP450 activity may alter the metabolism of other drugs
by either inhibiting the enzymatic pathway of CYP450 thus causing increased concentrations
of drugs resulting in toxicity. Other drugs may induce the CYP450 pathway thus reducing the
concentration of other drugs leading to subtherapeutic drug levels and treatment failures
(McDonnell & Dang, 2013). Each person’s ability to metabolize a drug is determined by the
pairing of alleles inherited from the mother and father (McDonell & Dang, 2013). Each allele
is categorized as a wild-type or variant. People who inherit two wild-type alleles generally
have normal rates of metabolism and are referred to as extensive metabolizers. People who
inherit two variant alleles will have little to no enzymatic activity and are referred to as poor
metabolizers. Lastly, those who inherit one wild-type and one variant allele have decreased
enzymatic activity and are referred to as intermediate metabolizers (McDonnell & Dang,
2013). Interracial variability and genetic mutations or polymorphisms are common in the
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CYP450 system and may cause unpredictable responses or affect the safety and efficacy of
drugs (McDonnell & Dang, 2013). According to Alessandrini et al. (2013), polymorphisms or
genetic variations account for 30% of interindividual differences seen in a variety of drug
responses however the clinical importance of this system has been extensively studied in the
Caucasian and Oriental population with limited data existing for African populations who
experience a heavy burden of communicable and non-communicable diseases. In a study by
Ramamoorthy et al. (2014) approximately 1/5 of new drugs approved in the previous 6 years
demonstrated differences in exposure and/or response across racial or ethnic groups leading to
population-specific prescribing recommendations. For example, rosuvastatin, a drug used to
treat hyperlipidemia, has a specific recommendation to initiate the drug at a lower dose for
Asians due to clinically relevant differences in pharmacokinetics (Ramamoorthy et al., 2014).
Tacrolimus, a drug used after organ transplantation to reduce the risk of organ rejection is
dependent upon a subtype of the CYP450 enzymatic system, CYP3A5, for metabolism
(Sanghavi, Brundage, Miller, Schladt, Israni, Guan, W…Jacobson, 2017). Sanghavi et al.
(2017), found that Tacrolimus has significantly different pharmacokinetics by race with
African Americans having variant alleles. In African Americans Tacrolimus has a 20% to 50%
lower bioavailability, higher drug clearance, and lower concentrations of Tacrolimus in the
blood compared to Caucasians requiring 1.5 to 2 times higher doses to achieve target blood
levels (Sanghavi et al., 2017).
The National Institute of Health (NIH) recognizes that the assumption that all that needs
to be learned about health and health care cannot be learned by studying mostly white male
participants. In response, the NIH required in 1993 that researchers who received funding report
9

race, ethnicity, and gender of participants in biomedical research (National Institute of health
[NIH], (1994).
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1.2 Theoretical Framework
The theoretical framework of this study is based upon the work of Crenshaw, the author
of the ground breaking essays, ‘Demarginalizing the Intersection of Race and Sex: A Black
Feminist Critique of Antidiscrimination Doctrine, Feminist Theory and Antiracist Politics’ and
‘Mapping the Margins: Intersectionality, Identity Politics, and Violence Against Women of
Color’ (Bowleg, 2012). Crenshaw coined the term “intersectionality” to address the
marginalization of black women within antidiscrimination law, feminist, and antiracist theory
and politics (Crenshaw, 1989). Crenshaw highlights the idea that black women are excluded
from feminist theory and antiracist politics because being black and female are predicated on
experiences that do not accurately reflect the intersection of race and gender. As
intersectionality makes its way into many disciplines including public health, sociology,
psychology, criminal justice, and education, its definition and focus have been dynamic.
Bowleg, expounded upon the work of Crenshaw with the article ‘The Problem with the Phrase
Women and Minorities: Intersectionality-an Important Theoretical Framework for Public
Health.’ Bowleg (2012) defines intersectionality as a theoretical framework that seeks to
highlight how multiple social identities such as race or ethnicity, gender, sexual orientation or
identity, socioeconomic status (SES), geographical location, and physical or mental disability
comingle at the microsocial level of individual experience to create systems of privilege and
oppression, such as racism, sexism, heterosexism, and classism at the macrosocial structural
level and how these interactions perpetuate the chasm of health care disparity. Intersectionality
has emerged as a means to address structural forms of inequality in health care.
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1.3 Statement of the Problem
Atrial fibrillation (AF) is the most common sustained rhythm disturbance encountered in
clinical practice (January, Wann, Alpert, Calkins, Cigarrora, Cleveland…Yancy, 2014). The
Centers for Disease Control and Prevention (CDC) (2017a) estimated 2.7 million to 6.1 million
people in the U.S. have been diagnosed with AF and that number is expected to increase to 8
million by 2050 (Calkins, Hindricks, Cappato, Kim, Saad, Aguinaga… Yamane, 2017). This
source does not delineate the incidence of AF by race or ethnicity. The incidence of AF
increases in prevalence with advancing age (January et al., 2014). Approximately 1% of patients
with AF are <60 years of age while up to 12% are 75-84 years of age (January, et al., 2014).
More than 1/3 of all patients with AF are >80 years of age (January, et al., 2014). For
individuals of European descent, the lifetime risk, which quantifies the absolute risk of
developing a disease of interest before death, of developing AF after 40 years of age is 26% for
men and 23% for women (January et al., 2014). Limited data exists on the incidence and
lifetime risk of AF in the African American and other ethnic populations because most studies
were performed with predominantly white participants of European origin (Mou, Norby, Chen,
O’Neal, Lewis, Loehr…Alonso, 2018). In an effort to narrow this chasm, Mou et al. (2018),
performed a large biracial study on participants from the Atherosclerotic Risks in Communities
Cohort (ARIC). The ARIC is a biracial prospective cohort study for the investigation of the
etiology of cardiac atherosclerosis and its clinical sequelae and variation in cardiovascular risk
factors, medical care, and disease based on race, sex, place, and time (The ARIC investigators,
1989). The cohort is composed of 15,792 participants recruited between 1987 to 1989 from
Washington County, MD; the northwest suburbs of Minneapolis, MN; Jackson, MS; and Forsyth
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County, NC (Mou et al., 2018). Of the participants, 55% were women and 27% were African
American reflecting the racial demographic of the underlying population of each community
with the exception of Jackson, MS, where only African Americans were sampled. At the time of
recruitment, the participants were between the ages of 45 to 64 years old (Mou et al., 2018).
Participants in the ARIC were examined three times in approximately 3–year intervals until 1998
with a final examination between 2011 and 2013. Examinations included carotid and popliteal
artery ultrasounds; lipid and lipoprotein analyses; coagulation, inhibition, platelet, and
fibrinolytic activity evaluations; and surveillance for coronary heart disease which involved the
review of hospitalizations and deaths of participants (Mou et al., 2018). Among the ARIC
cohort, Mou et al. (2018) included 15,343 participants in the study excluding the following; 48
participants with self-reported race as nonwhite or non-African American; 44 African Americans
from MN and MD due to small sample sizes; and 37 participants with AF or atrial flutter (AFL)
diagnosed by ECG at the initial visit (Mou et al., 2018). Baseline characteristics of the study
participants were 5332 (35%) white males, 5948 (39%) white females, 1539 (10%) African
American males, and 2524 (16%) African American females. Atrial fibrillation was identified
by electrocardiograms (ECG) from follow-up examinations, hospital discharge records, and
death certificates (Mou, et al., 2018). The study identified 2793 new cases of AF; 2272 in whites
and 521 in African Americans. Based on their findings the lifetime risk of AF was 36% in white
males, 30% in white females, 21% in African American males, and 22% in African American
females (Mou et al., 2018).
Atrial fibrillation is a growing problem in the U.S. The consequences of AF can be life
changing and life threatening (Calkins, Hindricks et al., 2017; Kim, Johnston, Chu, & Shulman,
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2011). Sotalol and dofetilide are two of the most popular and most efficient drugs used to treat
AF however the population studied to determine the efficacy and safety of these drugs was
overwhelmingly white (90%) and male (70%) (FDA, 2018c), therefore data assessing the
efficacy of these medications in non-whites and females are lacking. The outcome of this
research may help to confirm or determine the effectiveness of sotalol and dofetilide in nonwhites and females. Such results may contribute to literature in the field of cardiac
electrophysiology and lead to more diverse clinical trials in the future.
1.4 Purpose of the Study
This study seeks to determine if there is an association between gender and racial factors
in the conversion and sustainment of normal sinus rhythm (NSR) from paroxysmal or persistent
AF using sotalol or dofetilide at the 1-month, 3-month, and 6-month interval after drug loading.
Electrocardiograms performed at approximately the 1-month, 3-month, and 6-month intervals
will be used to evaluate each patient’s cardiac rhythm.
1.5 Research Questions
Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol between males and females at the 1-month, 3-month, and 6-month
post-loading interval?
Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using dofetilide between males and females at the 1-month, 3-month, and 6-month
post-loading interval?
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Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol between non-whites and whites at the 1-month, 3-month, and 6month post-loading interval?
Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using dofetilide between non-whites and whites at the 1-month, 3-month, and 6month post-loading interval?
1.6 Significance of the Study
This study brings to light the underrepresentation of non-whites and females in clinical
trials and specifically as it relates to sotalol and dofetilide. The Institute for Safe Medical
Practices (2018) considers sotalol and dofetilide high-alert medications. Per the Institute, “highalert medications are drugs that bear a heightened risk of causing significant harm in patients
when they are used in error” (p. 1). As sotalol and dofetilide can cause dangerous lifethreatening arrhythmias and renal failure, it is required by the FDA that the patient be placed in a
facility for a minimum of three days that can provide continuous electrocardiac monitoring,
cardiac resuscitation, calculations of kidney function, and the presence of personnel trained in
the management of serious ventricular arrhythmias for the initiation, re-initiation, and dose
adjustment of these medications (FDA, 2018c). Both sotalol and dofetilide can cause an increase
in the QT interval which is the time from the start of depolarization (contraction of the heart) to
the end of repolarization (relaxation of the heart). Increase in this interval longer than .500ms
can induce dangerous ventricular arrhythmias, primarily Torsades de Pointes, where the
ventricles of the heart beat faster than the atria creating a complex that spirals around the
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baseline of an ECG (Thaler, 2015). Torsades de Pointes may terminate on its own or could
deteriorate to ventricular fibrillation (VF) allowing no blood to flow to the rest of the body,
which can lead to cardiac arrest and death (Seymore, 2018).
A randomized, double-blind, placebo-controlled dose response trial evaluated the ability
of dofetilide to convert patients with persistent AF or AFL to NSR and to maintain NSR after
conversion. Nine hundred ninety-six patients were enrolled in the study and had a 1- week to 2year history of AF or AFL. Patients were randomized to placebo or doses of 125 mcg, 250 mcg,
or 500 mcg of dofetilide twice a day. The study found that at 6 months and 12 months 62% and
58% of patients, respectively, on dofetilide 500 mcg twice a remained in NSR; 50% and 37% of
patients, respectively, on 250 mcg of dofetilide twice a day remained in NSR; and 37% and 25%
of patients, respectively, on placebo remained in NSR (FDA, 2018c). The patient population in
this study was mostly white (90%) and male (>70%) and made no contribution to outcomes
related to non-whites nor females. The study also does not give the outcomes of patients on 125
mcg of dofetilide. In another U.S. multicenter, randomized, placebo-controlled, double-blind,
dose-response trial of patients with symptomatic primarily paroxysmal AF and AFL, three fixed
dose levels of sotalol 80 mg, 120 mg, and 160 mg twice daily were compared in 253 patients.
The study found the recurrence rate of AF or AFL at 12-months post-conversion was 67% on
placebo, 58% on 80 mg of sotalol, 49% on 120 mg of sotalol, and 42% on 160 mg of sotalol.
The patient population in this study was 64% male (FDA, 2018c). The European and Australian
Multicenter Evaluative Research on Atrial Fibrillation—Dofetilide, or the EMERALD trial,
performed to determine the effectiveness of dofetilide, found that dofetilide was an effective and
well tolerated treatment for AF, however of the 505 study participants, only 22 were female and
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there was no documentation of race (EMERALD, 1998). Although these studies do generally
address the efficacy of sotalol and dofetilide, the representation of females and non-white
participants were minimal. This research will address the efficacy of both drugs in males and
females as well as white and non-white patients.
1.7 Definition of Terms
Cardiac Electrophysiology. The study of the electrical system of the heart concerning the
mechanisms and therapy of cardiac arrhythmias (Fogoros, 2012).
Electrocardiogram. A 10-second recording of the innate biologic electrical activity of the heart
Arrhythmia. Disturbance of rate, regularity, or conduction of the cardiac impulse (Thaler, 2015).
Paroxysmal atrial fibrillation. Atrial fibrillation that terminates spontaneously or with
intervention within 7 days of onset (January et al., 2014).
Persistent atrial fibrillation. Continuous atrial fibrillation that is sustained for >7 days
Anti-arrhythmic drugs. Drugs that change the shape of the action potential thereby altering the
shape of the cardiac action potential and the conductivity and refractoriness of cardiac tissue to
reduce the likelihood of recurrence of reentrant circuits (Fogoros, 2012).
Sotalol. Class III anti-arrhythmic drug with class II properties that block potassium and betaadrenergic channels causing prolongation of the action potential and refractoriness in slow and
fast tissue channels (Fogoros, 2012).
Dofetilide. A pure class III anti-arrhythmic drug that blocks the rapid component of the cardiac
delayed rectifier potassium current prolonging the cardiac action potential and the effective
refractory period (McClellan & Markham, 1999).
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1.8 Assumptions
There is no association between males and females and whites and non-whites in the
conversion and sustainment of NSR from paroxysmal or persistent AF using sotalol or dofetilide
1.9 Limitations
There are many limitations that have been identified in this study. First, the study is
performed at one institution which limits generalization of findings. The patient population at
this institution is predominantly white and male which could translate into less information
regarding the efficacy of sotalol and dofetilide for non-whites and females. Each patient in the
study gave documentation of race, however this self-documented variable in some cases could be
inaccurate affecting study findings. The study also focuses exclusively on AF and excludes the
multitude of other dysrhythmias or dysrhythmias that may co-occur with AF. Some patients in
the study have been diagnosed with multiple dysrhythmias which may call for treatment
strategies beyond or other than the use of sotalol or dofetilide. These dysrhythmias could cause,
exacerbate, or interfere with treatment of AF. Comorbidities like hypertension (HTN), heart
failure, CAD, valvular heart disease, obstructive sleep apnea (OSA), and obesity are known to
increase the risk of AF as well as possibly reduce the success rate of treatment. This study does
not address the link between these comorbidities and the rate of conversion from AF to NSR
with the use of sotalol or dofetilide. Behavioral characteristics such as cigarette smoking, illicit
drug use disorder, alcohol use or use disorder, and excessive caffeine intake may play a part in
the success of treatment of AF. As well, medication compliance may also play a role. Though
patients are advised to discontinue these behaviors and fully comply with prescribing
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instructions, there is no reasonable way to assure compliance with these recommendations
beyond receiving their self-reported documentation. It is noteworthy that evaluation of the
patients ECG at the 1-month, 3-month, and 6-month interval may not give the full scope of the
patient’s heart rhythm as it relates to time spent in NSR or AF as the ECG only documents a 10second period of time while the patient is in the office. These patients may well be in AF or
other dysrhythmias at other times which would not be captured at the aforementioned intervals.
It is possible that patients may convert back to AF after the 6-month interval requiring more
aggressive treatment options like AF ablation, atrioventricular-node (AVN) ablation, pacemaker
implantation, etc. Progression of treatment has not been documented in this study.
1.10 Delimitations
Delimitations of this study are important and require mentioning in order to clearly
highlight necessary boundaries that helped to maintain a focus on the study at hand. First, study
subjects are limited to those with paroxysmal or persistent AF although there are many other
cardiac dysrhythmias that a patient may have. During the course of the drug-load, some patients
may require a direct-current cardioversion (DCCV) in order to promote NSR. Direct-currentcardioversion is a 200 to 360 Joules transthoracic electric shock of the patient’s heart that
depolarizes the entire myocardium rendering the heart momentarily refractory to repeat
depolarization. This allows the most rapid intrinsic pacemaker which is usually the SA node to
resume control of the heart’s rhythm, successfully converting the patient from AF to NSR
(Mitchell, 2019b). The rate of conversion to NSR for the patients receiving sotalol or dofetilide
who undergo DCCV compared to the patients who do not receive a DCCV during the drug
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loading process will not be compared. The method of treatment is limited to sotalol and
dofetilide as these are the most effective drugs for atrial fibrillation and are being used with more
frequency. Evaluation of ECGs at the 1-month, 3-month, and 6-month interval and not
continually monitoring the patients with various forms of devices reduces costs for the patient
that may not be clinically necessary. Lastly, including variables that may affect the outcome of
AF such as heart disease, HTN, OSA, DM, and obesity have already been studied, are well
documented, and would add no new information to the literature.
1.11 Conclusion
It is clear and evident in the literature that some medications, including sotalol and
dofetilide, studied in clinical trials with predominantly white male participants may be
ineffective in females and non-whites. This study will evaluate the effectiveness of sotalol and
dofetilide in males and females and white and non-whites at the 1-month, 3-month, and 6-month
interval after drug loading to determine if they remain in NSR.

20

CHAPTER II
REVIEW OF THE LITERATURE
This chapter contains seven sections: (1) search terms, (2) theoretical framework:
Intersectionality, (3) overview of AF, (4) physical manifestations of AF, (5) basic anatomy of the
cardiac electrical system, (5) mechanisms of AF, (6) and (7) treatment of AF.
2.1 Search Terms
Databases used to support this study included PubMed, Scopus, Google Scholar, and
ProQuest Health and Medical. Key search terms include: paroxysmal atrial fibrillation,
persistent atrial fibrillation, heart rhythm society, left atrium, action potential, treatment of atrial
fibrillation, anti-arrhythmic drugs, sotalol, dofetilide, inequities in clinical trials, diversity in
clinical trials, and intersectionality.
2.2 Theoretical Framework: Intersectionality
The purpose of this study is to evaluate the association between males and females and
whites and non-whites in the conversion and sustainment of NSR from paroxysmal or persistent
AF using sotalol or dofetilide. Non-whites and females are largely underrepresented in clinical
trials that determine the effectiveness and safety of drugs; therefore, this study seeks to
determine the effectiveness of the aforementioned drugs in these populations. The theoretical
framework of this study is based upon the work of Dr. Kimberlé Crenshaw, the author of the
groundbreaking essays, 'Demarginalizing the Intersection of Race and Sex: A Black Feminist
Critique of Antidiscrimination Doctrine, Feminist Theory and Antiracist Politics' and 'Mapping
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the Margins: Intersectionality, Identity Politics, and Violence Against Women of Color"
(Bowleg, 2012). In these works, Crenshaw introduced the term intersectionality to address the
marginalization of black women within antidiscrimination law, feminist, antiracist theory and
politics (Crenshaw, 1989). Crenshaw (1989) states that black women are sometimes excluded
from feminist theory and antiracist politics because being black and female are described and
represented with inaccurate experiences that do not adequately reflect the intersection of gender
and race. Crenshaw (1989) further states that the intersectional experience is “greater than the
sum of racism and sexism and that any analysis that does not take intersectionality into account
cannot sufficiently address the particular manner in which black women are subordinated" (p.
140). She goes on to expose the ways in which the law has historically defined the confines of
race and sex discrimination through the chosen representatives of white women and AfricanAmerican men leaving out black women and in essence pitting two resistance groups at odds
(Carbado, Crenshaw, Mays, & Tomlison, 2013). The concept of intersectionality is not a new
one, but dates back to 1851 in a groundbreaking speech by ex-slave Sojourner Truth (National
Park Services [NPS], 2017). Sojourner Truth was born into slavery in 1797 in New York. When
her master reneged on his promise to free her in 1827 in accordance to the New York Anti-Slave
law of 1827, Truth escaped (NPS, 2017). She went on to become one of the most powerful
activists for human rights, women’s rights, and the anti-slavery movement. In 1851 at a
Women’s Rights Convention in Akron, Ohio, Truth delivered what is now known as the most
poignant and powerful women’s rights and abolitionist speeches in American history, ‘Ain’t I a
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Woman?’ (NPS, 2017). In her speech, Truth describes the differing treatment of and sentiment
afforded to women based on race. She reads:
That man over there says that women need to be helped into carriages, and lifted over
ditches, and to have the best place everywhere. Nobody ever helps me into carriages, or
over mud-puddles, or gives me any best place! And ain't I a woman? Look at me! Look at
my arm! I have ploughed and planted, and gathered into barns, and no man could head
me! And ain't I a woman? I could work as much and eat as much as a man - when I could
get it - and bear the lash as well! And ain't I a woman? I have borne thirteen children,
and seen most all sold off to slavery, and when I cried out with my mother's grief, none
but Jesus heard me! And ain't I a woman? (NPS, 2017, p.1).
For other authors, intersectionality has further been described as an analytical paradigm
or theoretical framework "for understanding how multiple social identities such as race, gender,
sexual orientation, socioeconomic status (SES), and disability intersect at the micro social level
of individual experience to reflect interlocking systems of privilege and oppression (i.e. racism,
sexism, heterosexism, classism) at the macro social level" (Bowleg, 2012). Davis (2008) defines
intersectionality as “the interaction between gender, race, and other categories of difference in
individual lives, social practices, institutional arrangements, and cultural ideologies and the
outcomes of these interactions in terms of power” (p. 68).
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2.3 Critical Race Theory
The important prelude to intersectionality is the Critical Race Theory (CRT). The CRT
was developed by legal scholars in an effort to provide a critical analysis of race and racism from
a legal standpoint (University of California Los Angeles [UCLA], 2001). It recognizes that
racism is and has been interwoven into every system of American society including the law. It
explains that the individual racist is of no consequence in order to recognize that the institutional
racism dominant in American culture gives rise to the perpetuation of privilege for whites and
marginalization of people of color in general (UCLA, 2001). The CRT also denounces the
traditions of liberalism and meritocracy based upon the fact that legal discourse defines the law
as value-neutral and colorblind. As it pertains to liberalism, the government is posited as a
necessary entity to protect individuals from harm by others but may simultaneously pose a threat
to people’s liberty. Meritocracy, or the belief that everyone who works hard can attain wealth,
power, and privilege is denounced by the fact that each individual is not equally situated with the
same opportunities or resources for success, ignoring the systemic inequalities that institutional
racism provides (UCLA, 2001). Intersectionality and the CRT point to the multidimensional
dynamic of oppression and recognizes that race alone does not provide the answers to
disempowerment of the oppressed, but they highlight how a combination of discriminating
factors, i.e. gender, sexual orientation, SES, class, geographic location, age, and ableism
intertwine and manifest themselves in various settings (UCLA, 2001).
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2.4 Growth in Intersectionality
Intersectionality has had marked interdisciplinary and global travels (Carbado et al.,
2013). Intersectionality was initially introduced to highlight the fact that black women were not
recognized in feminist movements and antidiscrimination law. It has now traveled into public
health, biomedicine, sociology, education, history, psychology, and political science (Carbado et
al., 2013). For example, Roberts and Jesudason (2013) founders of the social justice
organization Generations Ahead, in their essay, ‘Movement Intersectionality: The Case of Race,
Gender, Disability, and Genetic Technologies’ describe lessons in applying insights from
intersectionality for coalition building and political change. They posit that intersectional
analysis can identify and emphasize commonalities and create solidarity between political
groups. They employ intersectionality to forge coalitions between previously adverse groups
helping them to acknowledge categorical differences and promote commonalities. Their focus is
to help differing groups use an intersectional lens to understand each other’s perspective on a
given issue revealing both privilege and victimhood, thereby forming a connection around shared
experiences of discrimination and marginalization (Carbado et al., 2013; Roberts & Jesudason,
2013). Cho (2013), author of ‘Post-Intersectionality: The Curious Reception of Intersectionality
in Legal Scholarship,’ advances the argument that intersectionality is always a work-in-progress
and that just because an intersectional analysis has not been done in a particular area of study
does not mean that it cannot be done. Cho also attacks the argument that just because the origin
of intersectionality centered around race and gender, specifically black women, it does not mean
that is immobile and cannot be engaged in other experiences, and that “race and gender
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intersectionality merely provided a jumping off point to illustrate the larger point of how identity
categories constitute and require political coalitions (Cho, 2013)” (390). Lastly, Artiles (2014),
in his article “Untangling the Racialization of Disabilities: An Intersectionality Critique Across
Disability Models,” argues that special education scholarship recognizes the importance of the
“racialization of disability.” Artiles goes on to explain the benefits and problems associated with
various models of examining disability and how intersectionality can be used to see beyond the
recognition that disability is racialized and imagine how this racialization is produced (Artiles,
2014; Carbado et al., 2013).
Bowleg (2012) compounded upon the work of Crenshaw in her article ‘The Problem with
the Phrase Women and Minorities: Intersectionality-an Important Theoretical Framework for
Public Health.’ In her assessment, intersectionality is a theoretical framework that seeks to
highlight how multiple social identities such as race or ethnicity, gender, sexual orientation or
identity, SES, geographical location, and physical or mental disability comingle at the micro
level of individual experience to create systems of privilege and oppression, such as racism,
sexism, heterosexism, and classism at the macro social-structural level and how these
interactions perpetuate the chasms of health care disparity (Bowleg, 2012). Bowleg (2012) takes
issue with the terms “women and minorities” being a staple population in the discourse of public
health. The NIH Policy and Guidelines on the Inclusion of Women and Minority Subjects in
Clinical Research 2001 amendment provided guidance on including women and minorities as
participants in research and reporting on sex, gender, race, and ethnicity. This amendment
implies that sex/gender and race/ethnicity are mutually exclusive. There is no recognition that
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these two categories can intersect as they do in racial and ethnic women (Bowleg, 2012).
Another confounding factor in this amendment according to Bowleg (2012) is that the word
“minority” is multifaceted and may not only include blacks, Hispanics, Asians, etc., but may
include lesbian, gay, bisexual, differently able, or mentally disordered people. She identifies that
using the terms minority and women erases the existence of people with multiple intersecting
discriminatory categorizations like a low-income Asian lesbian with a physical disability. She
further takes issue with the U.S. Department of Health and Human Services’ (DHHS) Health and
Humans Services Action Plan to Reduce Racial and Ethnic Health Disparities which
acknowledges that “characteristics such as race or ethnicity, religion, socioeconomic status
(SES), gender, age, mental health, disability, sexual orientation or gender identity, geographic
location, or other characteristics historically linked to exclusion or discrimination are known to
influence health status (DHHS, 2011a).” In her assessment the use of the term “or” perpetuates
the notion that these discriminatory categorizations do not intertwine and further ignores their
obvious intersection in many people. According to Bowleg (2012) acknowledgement of the
existence of multiple intersecting identities is the first step towards understanding the
complexities of health disparities for populations of historically oppressed groups. The other
step is the recognition of how these systems of privilege and oppression result in social
inequalities and maintain health disparities. According to Bowleg (2012) “the recognition of
intersectionality stands to benefit public health in 4 noteworthy ways:
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•

Providing a unifying language and theoretical framework for public health
scholars engaged in investigating intersections of race, ethnicity, gender, sexual
orientation, SES, and disability to reduce and eliminate health disparities,

•

Prompting public health scholars to conceptualize and analyze disparities and
social inequalities in health in the complex and multidimensional ways that mirror
the experiences of the population for whom adverse health outcomes are most
disproportionate,

•

Focusing on macro-level social-structural factors to consider the substantial
effects beyond the level of the individual on health, and

•

Taking the experiences of historically oppressed or marginalized populations as
its vantage point to facilitate and inform the development of well-targeted and
cost-effective health promotion, messages, interventions, and policies.”
2.5 Overview of Atrial Fibrillation

Atrial fibrillation is a supraventricular tachycardia(SVT) manifested by chaotic,
uncoordinated, and rapid activation of the atria (Calkins, Brugada, Packer, Cappato, Chen,
Grijns,…Shemin, 2009). On a surface 12-lead ECG a diagnosis of AF requires a rhythm strip
demonstrating irregular R-R intervals and no distinct P waves (Calkins, Hindricks et. al, 2017).
The irregularly irregular characteristic of the QRS complex in the absence of P waves is key to
identification of AF on a 12-lead ECG (Holler, 2008). The rapid activation of the atria may lead
to atrial heart rates of 300 to 500 beats per minute (bpm) and ventricular heart rates that may
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exceed the normal ventricular rate of 60-100 bpm (Thaler, 2015). The classification of AF
assists providers in determining the type of AF a patient may have as well as short-term and
long-term treatment strategies. Table 2-1 documents the classification system used in the 2014
American Heart Association/American College of Cardiology/Heart Rhythm Society
(AHA/ACC/HRS) Guidelines for Management of patients with Atrial Fibrillation (January et al.,
2014). Classification of Atrial Fibrillation
Table 2-1
Classification of Atrial Fibrillation
Paroxysmal AF

• AF that terminates spontaneously or with
intervention within 7 days of onset
• Episodes recur with varying frequency
• Continuous AF that is sustained for >7 days
• Continuous AF >12 months in duration
• The term “permanent AF” is used when the patient
and clinician make a joint decision to stop further
attempts to restore and/or maintain sinus rhythm

Persistent AF
Long-standing persistent AF
Permanent AF

• Acceptance of AF represents a therapeutic attitude
on the part of the patient and clinician rather than an
inherent pathological attribute of AF
• Acceptance of AF may change as symptoms,
efficacy of therapeutic interventions, and patient and
clinician preferences evolve

*AF indicates atrial fibrillation

2.6 Physical Manifestation of AF
The chaotic uncoordinated rapid activation of the atria leads to atrial dysynchrony, a
condition where the atria do not contract at the same time, which may result in reduction of the
filling of the left ventricle with enough blood to sustain adequate systemic perfusion and
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hemodynamic stability (Holler, 2008). This may cause patients with AF to experience symptoms
such as fatigue, shortness of breath (SOB), dyspnea on exertion (DOE), syncope, pre-syncope,
lightheadedness, dizziness, heart pounding, heart racing, and heart palpitations (Holler, 2008).
Symptoms may range from mild to severe and some patients may have no symptoms at all. Any
or all of these symptoms can negatively impact the patient’s quality of life. (Calkins, Hindricks
et al., 2017).
Due to its direct impact on patients and the severity of its complications it is important to
diagnose AF. Patients with AF have a 5-fold increase risk of stroke compared to those without
AF and an increased risk of sudden death (Calkins, Hindricks et al., 2017). According to the
CDC (2017a), 15%-20% of ischemic strokes caused by blood clots or fatty deposits in the
vasculature of the brain are attributed to AF. Also, AF related strokes are more severe than
strokes that are not related to AF (Calkins, Hindricks et al., 2017; Miller et al., 2005. Beyond
ischemic strokes, AF may also cause transient ischemic attacks (TIAs), systemic
thromboembolism, and cause or exacerbate heart failure (Wang et al., 2003). Atrial fibrillation
has also been linked to a 2-fold increase in dementia, (Calkins, Hindricks et. al, 2017; Jacobs et
al., 2015; Wang et al., 2003) and overall mortality (January et al., 2014). Populations with
comorbidities such as HTN, DM, thyroid disease, chronic kidney disease (CKD), structural,
valvular and ischemic heart disease, congestive heart failure, chronic obstructive pulmonary
disease (COPD), anemia, obesity, OSA, tobacco use, and alcohol use or use disorder are at
increased risk for the development and sustainment of AF as well as its complications (Amin et
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al., 2016; CDC, 2017a; Holler, 2008). Other risk factors include age, sex, race, family history,
and tall stature (Calkins, Hindricks et. al, 2017).
Combined with the complications and sequelae of AF, health care costs are also
impacted. In the U.S., AF accounts for more than 450,000 hospitalizations annually and
contributes to more than 99,000 deaths (Calkins, Hindricks et al., 2017; Kim et al., 2011). Atrial
fibrillation increases health care costs by $8700 per person resulting in a $26 billion increase to
national annual health care costs (Calkins, Hindricks et al., 2017; Ganesan, Chew, Hartshorne,
Selvanayagam, Aylward, Sanders…& McGavigan, 2016).
2.7 Anatomy of the Cardiac Electrical System
In the normally functioning heart, its electrical impulse originates in the sinoatrial (SA)
node located in the high right atrium (Fogoros, 2012). The impulse travels from the SA node
across Bachman’s Bundle to provide electrical activity to rest of the right atrium (RA) and the
left atrium (LA) (Thaler, 2015). From the SA node, the impulse spreads rapidly to the
atrioventricular (AV) node where its conduction is slowed in order to give the atria ample time to
completely empty its blood into the ventricles (Fogoros, 2012; Thaler, 2015). The impulse then
travels down to the Bundle of His to the ventricles via the His-Purkinjie system. The electrical
impulse follows the His bundle and travels into the right and left bundle branches. The branches
of the Purkinjie system delivers electrical impulses via Purkinjie fibers to the furthest reaches of
the ventricular myocardium which causes a brisk contraction from the ventricles (Fogoros,
2012). Figure 2-1 below represents the movement of the electrical impulse through the heart and
their manifestations on the ECG.
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Figure 2-1 ECG interpretation-Medicalbooksvn.wordpress.com, 2018
2.7.1.1 The Cells of the Heart and the Cardiac Electrical System
The heart is powered by innate biological electricity (Thaler, 2015). The ECG is a basic
tool used to record the electrical activity of the heart. It is through abnormalities identified on
the recording of the ECG that help in the diagnosis of cardiac dysrhythmias (Thaler, 2015). In
their resting state, cardiac or myocardial cells are electrically polarized meaning their inside is
negative with respect to their outside (Thaler, 2015). The voltage difference across the cell
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membrane is called the transmembrane potential which is -80 to -90 mV (Fogoros, 2012).
Electrical polarity is maintained by ion pumps that keep the appropriate distribution of ions,
mainly calcium, potassium, sodium, and chloride, in and out of the myocardial cell (Thaler,
2015). In turn, the result is an accumulation of negatively charged ions within the cell (Fogoros,
2012). When myocardial cells are stimulated there is loss of the internal negativity of the cell in
a process known as depolarization, which is the cardinal electrical event of the heart.
Depolarization is propagated from myocardial cell to myocardial cell in a wave that transcends
the entire heart representing a flow of electricity. When that wave reaches a myocardial cell, tiny
channels within the cell membrane open allowing for the influx of positively charged ions
changing its transmembrane potential, causing the cell to contract in a process called excitationcontraction coupling (Fogoros, 2012; Thaler, 2015). In this process the influx of calcium causes
actin and myosin, contractile proteins housed within the myocardial cell, to interact resulting in
contraction of the cell (Thaler, 2015). Once depolarization is complete, repolarization, which
brings myocardial cells back to their negative resting state, occurs by reversing the flow of ions,
primarily calcium, out of the myocardial cell causing it to relax. The waves seen on an ECG are
a representation of depolarization and repolarization (Thaler, 2015).
Graphed against time, each depolarization-repolarization cycle of the heart represents
what is called an action potential. Each action potential stimulates neighboring cells to
depolarize, generating their own action potential until the entire heart has been depolarized with
an action potential representing each and every myocardial cell (Fogoros, 2012; Thaler, 2015).
The heart spontaneously generates these electrical impulses which are vital for proper and
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sustained cardiac function. The pattern and timing of these impulses determine the rate and
rhythm of the heart (Fogoros, 2012).
2.7.1.2 The Action Potential
The action potential is divided into 5 phases; phase 0, phase 1, phase 2, phase 3 and phase
4. More simply, it can be thought of as the depolarization phase, repolarization phase, and the
resting phase (Fogoros, 2012). Phase 0, or depolarization, occurs when rapid sodium channels in
the cell membrane are stimulated to open causing positively charged sodium ions to rush into the
cell resulting in a rapid positively directed change in the transmembrane potential (Fogoros,
2012). The stimulation and depolarization of a cardiac cell propagates other nearby cells to
depolarize. Notably, the speed of depolarization of one cell determines the speed at which the
electrical impulse is propagated across the heart. Therefore, if the speed of depolarization is
changed, which would also change the slope of phase 0 of the action potential, the conduction
velocity of the cardiac tissue would also be changed (Fogoros, 2012). Once a cell is depolarized,
it cannot depolarize again until the ionic influx that occurred is reversed. Therefore, the period
between the end of phase 0 to late in phase 3 is called the refractory period of cardiac tissue
(Fogoros, 2012). Repolarization roughly correlates with phase 1 through phase 3 of the action
potential and represents the width of the action potential. It is understood to return the cardiac
action potential to the resting transmembrane potential of -80 to -90 mV (Fogoros, 2012). Phase
1 represents the start of repolarization, inclusive of inactivation of the sodium current, and
opening of the potassium channels. Phase 2 is thought to prolong the repolarization phase that
begins in phase 1. It is commonly known as the plateau phase mediated by slow calcium
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channels which allow positively charged calcium ions to slowly enter the cell, which prolongs
the refractory period (Fogoros, 2012). Phase 3 represents final rapid repolarization and
activation of calcium channels. Here, final rapid repolarization is mediated by a balance between
the slow inward and outward potassium current, inactivation of calcium current, and increased
outward current through delayed potassium channels (Forogos, 2012). The net membrane
current becomes outward and the cell repolarizes. Phase 4 is known as the resting phase or the
time period between action potentials (Fogoros, 2012). There is largely no net movement of ions
across the cell membrane, but for some cells this resting period is not quiet. There is a leakage
of ions back and forth across the cell membrane in order to cause a gradual increase in
transmembrane potential (Fogoros, 2012). When the transmembrane potential is high enough,
appropriate channels open to cause the cell to depolarize which will in turn spread across the
myocardium causing other cells to depolarize (Fogoros, 2012). This phase 4 activity is known as
automaticity, a mechanism by which the normal heart rhythm is established and maintained
(Fogoros, 2012). The illustration below represents the relationship of depolarization,
repolarization, the action potential, and ECG manifestations.
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Figure 2-2 Cardiac Action Potential
Teachme Physiology, 2020
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Figure 2-3 ECG PQRS Complex

2.7.1.3 Left Atrial Anatomy and Electrophysiological Mechanism of AF
The LA is the most posteriorly located chamber of the heart if viewed anteriorly from the
chest (Ho, Cabrera & Sanchez-Quintana, 2012b). The pulmonary veins (PV) enter the posterior
portion of the left atrium. These are called the right superior pulmonary vein (RSPV), the right
inferior pulmonary vein (RIPV), the left superior pulmonary vein (LSPV), and the left inferior
pulmonary vein (LIPV) (Ho, Cabrera & Sanchez-Quintana, 2012b). In a study performed on
post-mortem hearts, 74% of the patients had 4 PV orifices, 17% had 5 PV orifices, and 9% had a
common PV on the right or the left side (Ho, Cabrera & Sanchez-Quintana, 2004a). Myocardial
fibers extend into all the PVs for 1-2 cm (Calkins, Hindricks, et al., 2017). Pulmonary vein focal
electrical firing can act as a trigger to start and maintain AF (Gittenberger-deGroot, et al., 2003).
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Studies have shown that PV-sleeve myocytes have discrete ion channel and action potential
properties that predispose them to arrhythmogenesis (Calkins, Hindricks et al., 2017). Other
studies performed in rabbit and canine PVs demonstrate automaticity and triggered activity
during manipulations that enhance calcium loading while other studies suggest focal triggers
from PVs could have a shorter action potential duration versus the atrium due to larger delayedrectifier potassium currents and smaller inward calcium currents. Abrupt changes in fiber
orientation and sodium channel inactivation by reduced resting potentials may also promote
conduction abnormalities (Calkins, Hindricks et al., 2017).
2.7.2 Treatment of AF
Electrophysiology is the study of the electrical functioning of the heart with primary
concerns of mechanisms and therapies to treat cardiac dysrhythmias (Fogoros, 2012). The main
strategies for treating AF are to prevent thromboembolism or ischemic stroke with
anticoagulation, control the heart rate, and to restore the heart rhythm (Fogoros, 2012).
2.7.2.1 Anticoagulation
Atrial fibrillation, whether silent or symptomatic, paroxysmal, or persistent requires
protection from thromboembolism and stroke. Anti-thrombotic agents like Warfarin, low
molecular weight heparin (LMWH), anti-platelet drugs like aspirin and clopidogrel, and Direct
Oral Anti-Coagulants (DOACS) agents like dabigatran, apixaban, and rivoroxiban are being used
(January et al., 2014). In order to determine if a patient with AF needs an anti-thrombotic agent,
a risk stratification protocol known as the Cha2DS2VAS c (CHF, HTN, diabetes mellitus (DM),
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prior stroke, TIA or thromboembolism, vascular disease, age >65, age >75 years, female sex)
scheme is used. This risk stratification protocol assigns points to patients based on the following
criteria; patients with a history of CHF, HTN, DM, valvular heart disease, are 65-74 years of age,
or female sex are given 1 point for each positive factor; patients 75 years old or greater or who
have had a stroke, TIA, or thromboembolism are given 2 points for each positive factor (January
et al., 2014). Nine is the maximum score using this risk stratification scheme. A patient with a
score of 0 suggests a low risk for thromboembolism and may not require anticoagulation. A
patient with a score of 1 is considered low-moderate risk and should consider anticoagulation. A
patient with a score of 2 is considered moderate to high risk and should be treated with
anticoagulation (https://www.mdcalc.com/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk,
2019). The adjusted stroke rate per year increases from 1.3% with a Cha2DS2VASc score of 1 up
to 15.2% with a score of 9 (January et al., 2014).
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2.7.2.2 Rate Control
Controlling the heart rate or rate control is another important aspect in the treatment of
AF. The ideal adult ventricular heart rate is 60-100 bpm. Rate control may positively impact the
patient’s quality of life, reduce morbidity, and decrease the potential for developing tachycardiainduced cardiomyopathy (January et al., 2014). Beta-blockers (i.e. Metoprolol, Esmolol,
Carvedilol, and Sotalol) and non-dihydropyridine calcium channel blockers (i.e. Diltiazem and
Cardizem) are primarily used for rate control. Digoxin and Amiodarone are also used if there are
contraindications or adverse reactions to the patient or if rate control is not achieved with betablockers or non-dihydropyridine calcium channel blockers (January et al., 2014). When
considering which agent(s) to use for rate control, individual factors must be considered such as
the patient’s degree of symptoms, hemodynamic status, presence or absence of CHF, COPD, and
potential precipitants of AF (January et al., 2014). For example, patients with COPD should
avoid beta-blockers due to possible worsening of breathing conditions and patients with
decompensated heart failure should avoid non-dihydropyridine calcium channel blockers due to
potential worsening of their cardiac condition. In the acute setting when rapid control of the
heart rate is required due to hemodynamic instability intravenous (IV) beta-blockers, IV nondihydropyridine calcium channel blockers, and IV or oral Amiodarone may be used. Directcurrent cardioversion may be used in the acute and non-acute setting if the patient has been on
uninterrupted anticoagulation for at least 21 days (January et al., 2014). Anticoagulation is
necessary prior to DCCV due to the risk of clot formation in the LA caused by AF which could
lead to a stroke.
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2.7.2.3 Rhythm Control
The next approach to treatment of AF is rhythm control. This approach attempts to keep
the patient out of AF and in NSR which may also slow the progression of paroxysmal AF to
persistent AF. Persistent AF may lead to electrical and structural remodeling of the heart that
may become irreversible with time (Wijffels et al., 1995). According to Wijffels et al. (1995),
the duration of paroxysms of AF are important when considering progression to persistent AF.
Accordingly, they found that 31% of patients with paroxysms of AF shorter than 2 days
transitioned to chronic or persistent AF while 46% of patients with paroxysms of AF 2 days or
longer transitioned to chronic or persistent AF. Clinically, the more time a patient spends in AF
the more difficult it becomes to keep them in NSR rendering rhythm control methods more
difficult and less effective. Therefore, early intervention with rhythm control may be beneficial
(Cosio et al., 2008).
Rhythm control is achieved by utilizing antiarrhythmic drugs (AADs) (January et al.,
2014). Most AADs are grouped into 4 classes (I-IV) using the Vaughn-Miller system which
classifies AADs based on their dominant cellular effect on the cardiac action potential (Mitchell,
2017a). Class I drugs (i.e. Lidocaine, Flecainide, Mexiletine, and Propafenone) are sodium
channel blockers that block fast sodium channels slowing conduction in fast-channel tissues.
Class II drugs are beta blockers (i.e. Propranolol and Metoprolol) which are anti-sympathetic
nervous system agents that affect predominantly slow-channel tissues (SA node and AV node)
decreasing the rate of automaticity thereby slowing conduction velocity, and prolonging
refractoriness. Class III drugs (i.e. Amiodarone, Sotalol, and Dofetilide) are potassium channel
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blockers which prolong the action potential duration and refractoriness in slow and fast channel
tissues. Class IV drugs (i.e. Verapamil and Diltiazem) are non-dihydropyridine calcium channel
blockers which depress calcium-dependent action potentials in slow-channel tissues, thus
decreasing the rate of automaticity, slowing conduction velocity, and prolonging refractoriness
(Mitchell, 2017a). Sotalol has both Vaughan-Williams Class II beta-blocking activity as well as
Class III cardiac action potential duration properties. It prolongs the plateau phase of the cardiac
action potential in isolated myocardial cells, slows the heart rate, decreases AV nodal
conduction, and increases AV-nodal refractoriness (FDA, 2017b). Dofetilide has VaughnWilliams Class III antiarrhythmic activity by blocking potassium channels (FDA, 2018c). It
increases the monophasic action potential due to delayed repolarization, terminates AF, and
prevents its re-induction (FDA, 2018c). The net effect of these drugs is to cause interruption in
the area of the action potential that is responsible for AF or other dysrhythmias. The illustration
below provides a visual tool that shows where these drugs affect the action potential.
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Figure 2-4 AAD Effect on Action Potential
Many AADs and combinations of AADs are used to treat AF, however evaluation of each of
these is beyond the scope of this paper. Instead, this paper focuses on the use and effectiveness
of sotalol and dofetilide.
The Institute for Safe Medical Practices (2018) considers sotalol and dofetilide high-alert
medications. Per the Institute, “high-alert medications are drugs that bear a heightened risk of
causing significant harm in patients when they are used in error” (p. 1). As sotalol and dofetilide
can cause dangerous life-threatening arrhythmias and renal failure, it is required by the FDA that
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the patient be placed in a facility for a minimum of three days that can provide continuous
electrocardiac monitoring, cardiac resuscitation, calculations of kidney function, and the
presence of personnel trained in the management of serious ventricular arrhythmias for the
initiation, re-initiation, and dose adjustment of these medications (FDA, 2018c).
Loading patients onto sotalol and dofetilide requires the following process:
1. Electrocardiographic assessment: Prior to administration of the first dose of

sotalol or dofetilide, the corrected QT (QTc) must be measured with an average of 510 heart beats using the Bazett formula (FDA, 2018c). If the QTc is greater than 440
milliseconds (ms) or 500ms in patients with ventricular conduction abnormalities,
the medication is contraindicated. If the heart rate is less than 60 beats per minute,
the QT interval should be used.

Figure 2-5 GrepMed, 2019
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2. Calculation of the Creatinine Clearance: The starting dose of sotalol and

dofetilide will be based in part on the patient’s creatinine clearance. The creatinine
clearance must be calculated using the following formula:
Male= (140-age) x actual body weight in kilograms (kg)
72 x serum creatinine in milligrams per deciliter (mg/dl)
Female= (140-age) x actual body weight in kilograms (kg)
72 x serum creatinine in milligrams per deciliter (mg/dl)
Calculated Creatinine Clearance

Dofetilide Capsule Dose

>60 milliliters per minute (ml/min)

500 micrograms (mcg) twice a day

40-60 ml/min

250 mcg twice a day

20-<40 ml/min

125 mcg twice a day

<20 ml/min

dofetilide is contraindicated

*Twice a day is every 12 hours

Calculated Creatinine Clearance

Sotalol Capsule Dose

>60 milliliters per minute (ml/min)

160 mg twice a day

40-60 ml/min

120 mg twice a day

20-<40 ml/min

80 mg twice a day

<20 ml/min

sotalol is contraindicated

*Twice a day is every 12 hours

3. Assessment of electrolytes: Serum potassium should be at least 4 mEQ and serum

magnesium should be at least 2 mg/dl. If the patient’s serum potassium is below 4
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mEq they must receive 40 mEq daily of potassium while on dofetilide. If the
patient’s magnesium is below 2 mg/dl they must receive 2 mg of magnesium IV
push and the next day start on oral magnesium of 400 mg twice a day.
4. Select starting dose of sotalol or dofetilide: The starting dose of sotalol and

dofetilide should be selected based on the calculation of the QT or QTc and the
creatinine clearance.
5. Begin continuous cardiac monitoring: The patient should be placed on continued

cardiac monitoring prior to being given the first dose of sotalol or dofetilide.
6. First dose electrocardiographic assessment: Two to three hours after

administration of each dose of sotalol or dofetilide the QT or QTc must be
reassessed. If the QT or QTc has increased by more than 15% compared to the
baseline established in Step 1, is greater than ½ of the R-R interval, or greater than
500ms or 550ms in patients with ventricular conduction abnormalities, the following
adjustment in dosing must be made:
Starting dose of dofetilide

Adjusted dose of dofetilide

500 mcg twice a day

250 mcg twice a day

250 mcg twice a day

125 mcg twice a day

125 mcg twice a day

125 mcg once a day

*Twice a day is every 12 hours
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Starting dose of sotalol

Adjusted dose of sotalol

160 mg twice a day

120 mg twice a day

120 mg twice a day

80 mg twice a day

80 mg twice a day

80 mg once a day

*Twice a day is every 12 hours

7. Subsequent creatinine clearance and electrolyte assessment: The patient’s

creatinine clearance, potassium, and magnesium must be assessed each day during
the drug loading process. Based on the patient’s subsequent creatinine clearance
calculations, the following adjustments to the sotalol and dofetilide dosage should be
made;

Reduction in creatinine clearance

Starting dofetilide dose

Adjusted dofetilide dose

>60 milliliters per minute (ml/min)

500 micrograms (mcg) twice a day

Continue current dose

40-60 ml/min

250 mcg twice a day

125 mcg twice a day

20-<40 ml/min

125 mcg twice a day

Discontinue dofetilide

Reduction in creatinine clearance

Starting sotalol dose

Adjusted sotalol dose

>60 milliliters per minute (ml/min)

160 mg twice a day

Continue current dose

40-60 ml/min

120 mg twice a day

80 mg twice a day

20-<40 ml/min

80 mg twice a day

80 mg once a day

<20 ml/min

sotalol is contraindicated

sotalol is contraindicated

*Twice a day is every 12 hours

*Twice a day is every 12 hours
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8. Subsequent electrocardiographic assessment: Two to three hours after each

subsequent dose of sotalol or dofetilide the QT or QTc must be reassessed for at
least 5 doses. Patients must be continuously monitored by ECG for a minimum of
12 hours after pharmacological conversion to NSR has occurred (FDA, 2018c).
Since sotalol and dofetilide can cause an increase in the QT interval which could lead to
dangerous ventricular dysrhythmias, patients must be removed from any other drugs that may
increase the QT interval (i.e. Methadone, Amiodarone, and Zithromax). Patients should
discontinue these drugs for the specified amount of time (based on the drugs half-life) for the
drug to metabolize completely from the blood stream. As long as the patient remains on sotalol
or dofetilide, no QT prolonging drugs may be used.
2.7.2.4 Direct-Current-Cardioversion (DCCV)
Direct-current cardioversion is external electrical energy that is passed through the
patient’s heart via the thorax using between 200-360 Joules delivered by two paddles (Sucu,
Davutoglu, & Ozer, 2009). This is an effective treatment option for patients with AF and other
types of dysrhythmias to restore them to NSR. The patient is first sedated then has electrodes
attached to the chest and back. Direct-current cardioversion is then delivered as a shock. The
patient’s heart rhythm is evaluated subsequent to each shock. This procedure can be repeated
multiple times until the patient’s heart rhythm is back in NSR. If sustained NSR is not
established after an appropriately delivered number of DCCV shocks, the procedure is deemed
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unsuccessful and unable to restore NSR. Other treatment options should then be considered
(Mayo Clinic, 2019).
2.7.2.5 Radio Frequency Ablation (RFA) with Pulmonary Vein Isolation (PVI)
Radiofrequency energy is a heat source used to create scarring in the tissue (HRS, 2019).
In radiofrequency ablation (RFA), catheters are advanced from the right femoral vein in the groin
and into the RA via the inferior vena cava. The septum of the heart is then punctured to access the
LA. Radiofrequency energy is then used to create a scar around each PV by creating point-bypoint circumferential lesions around each vein isolating them from the body of the LA (HRS,
2019). This technique attempts to control the triggers of AF by blocking the electrical signals
generated by the PVs thereby reducing or eliminating the frequency of AF (Gittenberger-deGroot,
et al., 2003).
2.8 Conclusion
In conclusion, the exclusion of females and non-whites from clinical trials and the impact
this has on the safety and efficacy of medications in these populations has been displayed. This
chapter has described an overview of cardiac anatomy, electrophysiology, atrial fibrillation, and
treatment mechanisms. It is noteworthy that there are many types of cardiac rhythm disturbances
and other medical and procedural treatment options available such as atrioventricular node
(AVN) ablation and the insertion of pacemakers, that are beyond the scope of this paper.
Chapter III describes the methods for this research study.
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CHAPTER III
RESEARCH METHODOLOGY
The focus of this study is to explore the association between males and females and whites
and non-whites in the conversion and sustainment of NSR from paroxysmal or persistent AF using
sotalol or dofetilide.
This chapter begins with a description of the study design, research setting, and study
population which will include a complete demographic table. This will follow with a description
and explanation of the independent variables, dependent variables, a statistical model, and
conclude with the statistical analysis of the data.
3.1 Research Design
This is a secondary data analysis performed on the existing data of all patients diagnosed
with paroxysmal or persistent AF who were treated with sotalol or dofetilide between January 1,
2018 and December 19, 2019 to determine the relationship of the independent and dependent
variables listed below. The patients evaluated in this study represents all of the available patients
with paroxysmal or persistent atrial fibrillation who were treated with sotalol or dofetilide during
this time period.
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3.2 Research Questions
Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol between males and females at the 1-month, 3-month, and 6-month
post-loading interval?
Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using dofetilide between males and females at the 1-month, 3-month, and 6-month
post-loading interval?
Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol between whites and non-whites at the 1-month, 3-month, and 6month post-loading interval?
Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using dofetilide between whites and non-whites at the 1-month, 3-month, and 6month post-loading interval?
3.3 Hypothesis
There is no association between males and females or whites and non-whites in the
conversion and sustainment of NSR from paroxysmal or persistent AF using sotalol or dofetilide.
3.4 Study Site
The study was performed at a 409 licensed-bed primary, acute, and specialty care system
in the Midwest. It is a teaching hospital and one of largest health systems in West Michigan with
375 physicians, 3,500 colleagues, 17,000 inpatient discharges, and nearly 145,000 emergency
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and/or urgent care visits annually. It offers a number of specialty care services, including
cardiothoracic surgery, cardiac electrophysiology, neurosurgery, orthopedics, bariatric surgery and
spine services (Mercy Health, 2019). The catchment area of the site is urban and rural with a
population of approximately 558,000. The served population is 84.6% white, 3.6% black, 8%
Hispanic, 1% native American Indian/Alaskan, and 1% Asian (Community Health Needs
Assessment, 2019).
3.5 Data Collection and Study Population
Patient’s records were accessed via the participating institution’s electronic health record.
All patient records accessed were loaded onto sotalol or dofetilide for paroxysmal or persistent
atrial fibrillation between January 1, 2018 to December 19, 2019. Obtained from the patient’s
record were the type of atrial fibrillation diagnosed, the medication sotalol or dofetilide, ECG
results at their 1-month, 3-month, and 6-month follow-up appointments, race, and gender.
Identifiable patient information such as names, social security numbers, dates of birth and
addresses were not used.
3.6 Independent Variables
Paroxysmal AF. Paroxysmal AF terminates spontaneously or with intervention within 7 days of
onset with episodes that may recur with varying frequency (January et al., 2014).
Persistent AF. Persistent AF is continuous and sustained for more than 7 days (January et al.,
2014).
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Gender and Race. Women of European descent have a lifetime risk of developing AF after the
age of 40-years old of 23% (January et al., 2014). Though the risk of developing AF in women
is significant, studies have borne out that the population in clinical trials for the development of
medication, including sotalol and dofetilide, are overwhelmingly white and male (Perez-Stable,
2018).
Dofetilide. Dofetilide has been found to be effective in converting and maintaining patients with
AF in NSR (FDA, 2018c).
Sotalol. Sotalol has been found to be effective in converting and maintaining patients with AF in
NSR though it does not appear to be as effective as dofetilide (FDA, 2018c).
3.7 Dependent Variables
ECG Results at 1-month follow up. The patient’s ECG is evaluated 1-month post sotalol or
dofetilide load to ensure the patient is in NSR and that the QT or Q Tc has not prolonged.
Prolongation of the QT or QTc may call for dose adjustment or discontinuation. Early in the
treatment process, it is important to keep the patient in NSR as much as possible while the heart
remodels and the left atria shrinks which reduces the chances of recurrence of AF. If a patient is
found to be in AF 1 month following drug-loading, they will be offered DCCV as a means to
reestablish NSR.
ECG Results at 3 and 6-month follow-up. The patient’s ECG is evaluated 3-months post
sotalol or dofetilide load again to ensure maintenance of NSR and that the QT or QTc has not
prolonged. If the patient’s QT or QTc has prolonged dose adjustment or discontinuation may be
necessary. If the patient is found to be in AF at 3-months post drug-loading DCCV may be
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offered along with continuation of the drug in an attempt to obtain long-term effectiveness. If
the patient does not desire to have a DCCV performed, then advancement of treatment options
may be considered such as AF ablation with PVI or AV-node ablation, and the insertion of a
pacemaker. If the patient’s QT or QTc has prolonged at the 6-month follow up it would be
determined that the medication may not be safe for the patient and advancement of treatment
strategies may be considered.
3.8 Statistical Model
Persistent or Paroxysmal AF

Female

Male

Non-White

White

Sotalol

Dofetilide

ECG 4-weeks,
3- months, 6
months

Descriptive Statistics

Pearson’s chi square analysis

Cross-tabulation of independent and
dependent variables

3.9 Data Analysis
A secondary data analysis was performed to assess the relationships of the independent
and dependent variables listed above. Using SPSS v. 24 descriptive statistics were obtained and
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initially evaluated for accuracy with histograms. A cross-tabulation frequency table was
produced to determine the number of variables that fell into each category. Following this, the
frequencies were checked to ensure that the assumption for chi-square had been met. As the chisquare assumption had not been met with respect to race, this variable was discarded for future
data analysis. Cross-tabulation was continued with the independent variables type of atrial
fibrillation and medication. Chi-square analysis to determine statistical significance was violated
due to cells having expected counts less than 5, therefore Fisher’s Exact was analyzed in order to
determine statistical significance. Fisher’s Exact revealed insignificant p-values for each
analysis requiring acceptance of the null hypothesis that there is no association between the
independent and dependent variables. Logistic regression was not performed as cross-tabulation
and Fisher’s exact revealed that the variables in question were not dependent. Human Subjects
Review Board approval was obtained at Western Michigan University and the participating study
site.
3.10 Conclusion
This chapter describes the research design, research questions, hypothesis, data
collection, and analysis for this study. Chapter IV will describe the results of the study.
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CHAPTER IV
RESEARCH FINDINGS
4.1 Results
Based on the methodology described in the previous chapter, this chapter presents, the
data analysis, and results of the study. A review of the purpose of the study and research
questions will be presented first. Next, the descriptive findings of the study subjects are
presented along with data analysis to answer research questions. The chapter concludes with
racial and gender comparison results detailing the comparison of sotalol and dofetilide.

4.2 Purpose of the Study and Research Questions
The purpose of this study was to evaluate the association between males and females, and
whites and non-whites in the conversion and sustainment of NSR from paroxysmal or persistent
AF using sotalol or dofetilide.
This chapter addresses the overall hypothesis and the four defining research questions. The
hypothesis is as follows: There is no association between males and females or whites and nonwhites in the conversion and sustainment of NSR from paroxysmal or persistent AF using sotalol
or dofetilide. The four defining research questions developed to explore the hypothesis include:
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1. Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol between males and females at the 1-month, 3-month, and 6month post-loading interval?
2. Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using dofetilide between males and females at the 1-month, 3-month, and
6-month post-loading interval?
3. Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol between whites and non-whites at the 1-month, 3-month, and
6-month post-loading interval?
4. Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using dofetilide between whites and non-whites at the 1-month, 3-month,
and 6-month post-loading interval?

4.3 Descriptive Findings of Study Sample
This section of Chapter IV describes the data collection and demographics of the catchment
area and study participants. Data analysis of the independent and dependent variables are
described and displayed in table format. Finally, statistical analysis is described and displayed in
table format which leads to the next section of Chapter IV to answer the research questions.
The subjects of the study were obtained from the electrophysiology program of the
participating institution from 1/1/2018 to 12/19/2019. The researcher obtained data from the
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electronic heath record of patients diagnosed with paroxysmal and persistent AF who were
loaded onto sotalol or dofetilide. The sample for the study included 84 subjects.
4.3.1 Demographics
The catchment area of the participating institution is urban and rural and consists of
approximately 558,000 people. Of the population served by this institution, 84.6% are white,
3.6% are black, 8% are Hispanic, 1% are Native American Indian/Alaskan, and 1% are Asian
(see Table 4-1).
Table 4-1
Demographic Data of Catchment Area of the Participating Institution
Racial/Ethnic Category

White
Black
Hispanic
Native American
Asian

Total

Percentage of Total

n=558,000

%

472,068
200,888
44,640
5,580
5,580

84.6%
36.0%
8.0%
1.0%
1.0%

Data were collected by review of patient’s chart via the electronic health record of the
participating institution. Eighty-four subjects met the inclusion criteria for study which were a
diagnosis of persistent or paroxysmal AF, loaded on to sotalol or dofetilide between 1/1/2018 to
12/19/2019, taking sotalol or dofetilide during the study period, and having had at least one postdrug load ECG. Of the 84 subjects included in the study, 59 were male, 29 were female, 80 were
white, 4 were non-white, 62 had a diagnosis of persistent AF, 22 had a diagnosis of paroxysmal
AF, 73 were loaded onto dofetilide, and 11 were loaded on to sotalol (see Table 4-2). Race was
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excluded from further study as there were not enough non-white study subjects to satisfy
statistical analysis. Table 4-3 displays the summary of dependent variables.
Table 4-2
Demographic Summary of the Independent Variables
Total
n=84

Percentage of Total
%

Male
Female

55
29

65.5
34.5

White
Non-white

80
4

95.2
4.8

Gender

Race

Table 4-3
Demographic Summary of the Dependent Variables
Post-drug load ECG

Total

NSR

1-month
79
66
3-month
76
65
6-month
75
61
Notes. ECG=electrocardiogram; NSR=normal sinus rhythm; AF=atrial fibrillation

AF/other
13
11
14

4.4 Data Analysis
Pearson’s chi-square and Fisher’s Exact tests were used to explore associations between
dichotomous categorical independent variables (type of AF, medication, and gender) and
dichotomous categorical dependent variables (1-month ECG, 3-month ECG, and 6-month ECG
readings). The null hypothesis is as follows: There is no association between males and females
or whites and non-whites in the conversion and sustainment of NSR from paroxysmal or
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persistent AF using sotalol or dofetilide. Table 4-4 describes the association between gender and
the type of AF and the outcome of the 1-month post-drug load ECG.

Table 4-4
Association Between Gender and Type of AF on 1-month post drug load ECG (DV), n=79
Gender
Type of AF
NSR (%)
AF/other (%)
Total (%)
Sig*
Female

paroxysmal
persistent

5 (100)
16 (72.7)

0 (0.0)
6 (27.3)

5 (100)
22 (100)

0.555

Male

paroxysmal
persistent

15 (93.8)
30 (83.3)

1 (6.3)
6 (16.7)

22 (100)
36 (100)

0.415

Total

paroxysmal
persistent

20 (95.2)
46 (79.3)

1 (4.8)
12 (20.7)

21 (100)
58(100)

0.167

Note. AF=atrial fibrillation. NSR=normal sinus rhythm. Sig*=Fishers Exact

Analysis found that 100% of females with paroxysmal AF converted to NSR compared to
93.8% of males at the 1-month post-drug load period. In patients with persistent AF, 72.7% of
females converted to NSR at the 1-month post-drug load period compared to 83.3% of males.
Primary outcome results indicate a non-significant association between males and females and
the type of AF in the conversion and sustainment of NSR using sotalol or dofetilide at the 1month post-drug load period p=.167. See Table 4-4.
Table 4-5 describes the association between gender and the type of AF and the outcome
of the 3-month post-drug load ECG. Analysis found that 100% of females with paroxysmal AF
converted to NSR compared to 100% of males at the 3-month post-drug load period. In patients
with persistent AF, 81.8% of females converted to NSR at the 3-month post-drug load period
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compared to 79.4% of males. Primary outcome results indicate a non-significant association
between males and females and the type of AF in the conversion and sustainment of NSR from
paroxysmal AF or persistent AF using sotalol or dofetilide at the 3-month post-drug load period
p=.057. See Table 4-5.

Table 4-5
Association Between Gender and Type of AF on 3-month post drug load ECG, n=76
Gender

Female

Male

Type of AF

NSR (%)

AF/other (%)

Total (%)

Sig*

paroxysmal
persistent

5 (100)
18 (81.8)

0 (0.0)
4 (18.2)

5 (100)
22 (100)

0.561

paroxysmal
persistent

15 (100)
27 (79.4)

0 (0.0)
7 (20.6)

15 (100)
34 (100)

0.084

Total

paroxysmal
20 (100)
0 (0.0)
20 (100)
persistent
45 (80.4)
11 (19.6)
56 (100)
Note. AF=atrial fibrillation. NSR=normal sinus rhythm. Sig*=Fishers Exact

0.057

Table 4-6 describes the association between gender and the type of AF and the outcome
of the 6-month post-drug load ECG. Analysis found that 100% of females with paroxysmal AF
converted to NSR compared to 71.4% of males at the 6-month post-drug load period. In patients
with persistent AF, 86.4% of females converted to NSR at the 6-month post-drug load period
compared to 80.0% of males. Primary outcome results indicate a non-significant association
between males and females and the type of AF in the conversion and sustainment of NSR from
paroxysmal AF or persistent AF using sotalol or dofetilide at the 6-month post-drug load period
p=.446. See Table 4-6.
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Table 4-6
Association Between Gender and Type of AF on 6-month post drug load ECG, n=76
Gender

Type of AF

NSR (%)

AF/other (%)

Total (%)

Sig*

Female

paroxysmal
persistent

4 (100)
19 (86.4)

0 (0.0)
3 (13.6)

4 (100)
22 (100)

0.592

paroxysmal
persistent

10 (71.4)
28 (80)

4(28.6)
7 (20.0)

14 (100)
35 (100)

0.084

16 (100)
57 (100)

0.446

Male

Total

paroxysmal
14 (77.8)
4 (22.2)
persistent
47 (85.2)
10 (17.5)
Note.AF=atrial fibrillation. NSR=normal sinus rhythm. Sig*=Fishers Exact

Table 4-7 describes the association between gender and the use of dofetilide or sotalol
and the outcome of the 1-month post-drug load ECG. Analysis found that 85.5% of females on
dofetilide converted to NSR compared to 89.4% of males at the 1-month post-drug load period.
In patients on sotalol, 50.0% of females converted to NSR at the 1-month post-drug load period
compared to 80.0% of males. Primary outcome results indicate a statistically significant
association between males and females and the use of sotalol or dofetilide in the conversion and
sustainment of NSR from paroxysmal AF or persistent AF at the 1-month post-drug load period
p=.015. See Table 4-7. In evaluation of this statistically significant result future research on a
larger and more gender diverse sample size is needed to clearly understand this particular
outcome.
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Table 4-7
Association Between Gender and Medication on 1-month post drug load ECG (DV), n=79
Gender
Female

Male

Medication

NSR (%)

AF/other (%)

Total (%)

Sig*

dofetilide
sotalol

18 (85.5)
3 (50.0)

3 (14.3)
3 (50.0)

21 (100)
6 (100)

0.101

dofetilide
sotalol

42 (89.4)
3 (60.0)

5 (6.3)
2 (40.0)

47 (100)
5 (100)

0.129

68 (100)
11 (100)

0.015

Total

dofetilide
60 (88.2)
8 (11.8)
sotalol
6 (54.4)
5 (45.5)
Note.AF=atrial fibrillation. NSR=normal sinus rhythm. Sig*=Fishers Exact

Table 4-8 describes the association between gender and the use of dofetilide or sotalol
and the outcome of the 3-month post-drug load ECG. Analysis found that 85.7% of females on
dofetilide converted to NSR compared to 86.7% of males at the 3-month post-drug load period.
In patients on sotalol, 83.3% of females converted to NSR at the 3-month post-drug load period
compared to 75.0% of males. Primary outcome results indicate a non-significant association
between males and females and the use of sotalol or dofetilide in the conversion and sustainment
of NSR from paroxysmal AF or persistent AF at the at the 3-month post-drug load period
p=.444. See Table 4-8.
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Table 4-8
Association Between Gender and Medication on 3-month post drug load ECG, n=76
Gender

Medication

NSR (%)

AF/other (%)

Total (%)

Sig*

Female

dofetilide
sotalol

18 (85.7)
5 (83.3)

3 (14.3)
1 (16.7)

21 (100)
6 (100)

1

dofetilide
sotalol

39 (86.7)
3 (75.0)

6 (13.3)
1 (25.0)

45 (100)
4 (100)

0.472

66 (100)
10 (100)

0.444

Male

Total

dofetilide
57 (86.4)
9 (13.6)
sotalol
8 (80)
2 (20)
Note.AF=atrial fibrillation. NSR=normal sinus rhythm. Sig*=Fishers Exact

Table 4-9 describes the association between gender and the use of dofetilide or sotalol
and the outcome of the 6-month post-drug load ECG. Analysis found that 90% of females on
dofetilide converted to NSR compared to 77.8% of males at the 6-month post-drug load period.
In patients on sotalol, 83.3% of females converted to NSR at the 6-month post-drug load period
compared to 75.0% of males. Primary outcome results indicate a non-significant association
between males and females and the use of sotalol or dofetilide in the conversion and sustainment
of NSR from paroxysmal AF or persistent AF at the 6-month post-drug load period p=.598. See
Table 4-9.
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Table 4-9
Association Between Gender and Medication on 6-month post drug load ECG, n=75
Gender

Medication

NSR (%)

AF/other (%)

Total (%)

Sig*

Female

dofetilide
sotalol

18 (90.0)
5 (83.3)

2 (10.0)
1 (16.7)

20 (100)
6 (100)

0.562

dofetilide
sotalol

35 (77.8)
3 (75.0)

10 (22.2)
1 (25.0)

45 (100)
4 (100)

0.652

65(100)
10(100)

0.598

Male

Total

dofetilide
53 (81.6)
12 (18.5)
sotalol
8 (80.0)
2 (20.0)
Note.AF=atrial fibrillation. NSR=normal sinus rhythm. Sig*=Fishers Exact

1.

Research Questions 1 and 2— Association in the conversion and sustainment of
NSR from paroxysmal or persistent AF using sotalol or dofetilide between males
and females at the 1-month, 3-month, and 6-month post-loading interval.

Pearson’s chi-square test was performed on the entirety of the data to determine if there
was a significant association between the dependent and independent variables. A total of 79
ECGs were obtained one-month post-drug loading. At the one-month post-drug loading
period, 5 (100%) females with paroxysmal AF had converted to NSR compared to 15
(93.8%) males with paroxysmal AF; and 16 (72.7%) females with persistent AF had
converted to NSR compared to 30 (83.3%) males with persistent AF. The test assumption
for Pearson’s chi-square and cross-tabulation analysis requires expected cell counts to be
above 5. This analysis found that 6 cells had an expected value less than 5, therefore Fisher’s
Exact test was used to evaluate statistical significance. Based on Fisher’s Exact test, there
was no significant association between gender and conversion and sustainment of NSR from
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paroxysmal or persistent AF at the one-month post-drug loading period, p=.167. See Table
4-4.
A total of 76 ECGs were obtained three-months post-drug loading. At the three-month postdrug loading period, 5(100%) females with paroxysmal AF had converted to NSR compared to
15(100%) males with paroxysmal AF; and 18 (81.8%) females with persistent AF had converted
to NSR compared to 27 (79.4%) males with persistent AF. The test assumption for Pearson’s
chi-square and cross-tabulation analysis were violated rendering the need for Fisher’s exact test
which found no significant association between gender and conversion and sustainment of NSR
from paroxysmal or persistent AF at the three-month post-drug loading period, p=.057. See
Table 4-5.
A total of 75 ECGs were obtained six-months post-drug loading. At the six-month post-drug
loading period, 4 (100%) females with paroxysmal AF had converted to NSR compared to 10
(71.4%) males with paroxysmal AF; and 19 (84.4%) females with persistent AF had converted to
NSR compared to 28 (80.0%) males with persistent AF. The test assumption for Pearson’s chisquare and cross-tabulation analysis were violated with a total of 5 cells having expected cell
counts less than 5, therefore Fisher’s exact test was evaluated to determine statistical
significance. Fisher’s exact test found no significant association between gender and conversion
and sustainment of NSR from paroxysmal or persistent AF at the six-moth post-drug loading
period, p=.446. See Table 4-6.
Pearson’s chi-square test and cross-tabulation were used to evaluate an association between
gender and the use of sotalol or dofetilide and the conversion and sustainment of NSR from
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paroxysmal or persistent AF at the 1-month, 3-month, and 6-month post-drug loading intervals.
At the 1-month post-drug loading interval 79 ECGs were evaluated. Twenty-seven of the
patients were female and 52 of the patients were male. Of the 27 female patients, 21 were on
dofetilide and 6 were on sotalol. Of the 52 male patients, 47 were on dofetilide and 5 were on
sotalol. At the 1-month post-drug load interval, 18 (85.5%) of females on dofetilide had
converted to NSR compared to 42 (89.4%) of males on dofetilide; and 3 (50%) of females on
sotalol had converted to NSR compared to 3 (60%) of males on sotalol. Test assumption for
Pearson’s chi-square test had been violated, therefore Fisher’s exact test found a statistically
significant association between gender and the use of sotalol or dofetilide in the conversion and
sustainment of NSR from paroxysmal or persistent AF, p=.015. Expected and observed counts
in this evaluation were nearly equal. The significance of this value will benefit from future
research on a larger and more gender diverse sample size to clearly understand this particular
outcome. See Table 4-7.
At the 3-month post-drug loading interval 76 ECGs were evaluated. Twenty-seven patients
were female, and 49 patients were male. Of the 27 female patients, 21were on dofetilide and 6
were on sotalol. Of the 49 male patients, 45 were on dofetilide and 4 were on sotalol. At the 3month post-drug load interval, 18 (85.7%) of females on dofetilide had converted to NSR
compared to 39 (8.7%) of males on dofetilide; and 5 (83.3%) of females on sotalol had converted
to NSR compared to 3 (75%) of male on sotalol. Test assumption for Pearson’s ci-square test
had been violated, therefore Fisher’s exact test found no significant association between gender
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and the use of sotalol or dofetilide in the conversion and sustainment of NSR from paroxysmal or
persistent AF, p=.444. See Table 4-8.
At the 6-month post drug loading interval 75 ECGs were evaluated. Twenty-six patients
were female, and 49 patients were male. Of the 26 female patients, 20 were on dofetilide and 6
were on sotalol. Of the male patients, 45 were on dofetilide and 4 were on sotalol. At the 6month post-drug load interval, 18 (90%) of the females on dofetilide had converted to NSR
compared to 35 (77.8%) of males on dofetilide; and 5 (83.3%) of females on sotalol had
converted to NSR compared to 3 (75%) of males on sotalol. Test assumption for Pearson’s cisquare test had been violated, therefore Fisher’s exact test found no significant association
between gender and the use of sotalol or dofetilide in the conversion and sustainment of NSR
from paroxysmal or persistent AF a the 6-month drug-loading interval, p=.598. See Table 4-9.
2.

Research Questions 3 and 4—Association in the conversion and sustainment of NSR
from paroxysmal or persistent AF using sotalol or dofetilide between non-whites and
whites at the 1-month, 3-month, and 6-month post-loading interval.

Evaluating the association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol or dofetilide between non-whites and whites at the 1-month, 3-month,
and 6-month post-drug loading interval was not able to be assessed due to the lack of non-white
subjects in the study. This question may be addressed with a more racially diverse larger sample
size.

68

4.4.1 Hypothesis
The null hypothesis is as follows: There is no association between males and females or
whites and non-whites in the conversion and sustainment of NSR from paroxysmal or persistent
AF using sotalol or dofetilide. No statistical significance was found in the conversion and
sustainment of NSR in either of these groups, therefore the null hypothesis is accepted in this
sample.
4.5 Conclusion
In conclusion, this chapter has analyzed demographic data from the catchment area of the
study as well as the study subjects. Data were compared between females and males and whites
and non-whites and the conversion and sustainment of NSR from paroxysmal or persistent AF
using sotalol or dofetilide at the 1-month, 3-month, and 6-month post drug-loading intervals.
Chapter V will provide a discussion of the findings, limitations, and future research needed in
this area.
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CHAPTER V
CONCLUSIONS, DISCUSSION, AND RECOMMENDATIONS FOR FUTURE
RESEARCH
5.1 Introduction
The following chapter concludes this report. A review of the research problem and
purpose of the study will be presented followed by a discussion and interpretation of the findings
based on the research questions. The chapter will conclude with a description of limitations and
recommendations for future research.
5.2 Statement of the Problem
Based on the literature, it has been shown that the safety, efficacy, and side effects of
drugs vary based on gender, racial, ancestral, and ethnic lines (Knepper & McLeod, 2018). In
the clinical trials performed to develop and market new drugs, females and non-whites are
largely underrepresented rendering the safety and efficacy data obtained for these groups
insufficient (King, 2002). As a result of the data being derived from predominantly white male
cohorts, these data may then be inappropriately extrapolated for clinical use in females and nonwhites resulting in consequential adverse outcomes ranging from mild to severe side-effects to
death (Ramamoorthy, et al., 2013). Post-market studies and reporting from FAERS may
subsequently reveal patterns of adverse outcomes potentially leading to FDA regulation of drugs
that may include labeling restrictions, post-market population specific prescribing, black-box
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warnings, and in some cases, revocation of FDA approval (Ramamoorthy et al., 2013; Weyant,
2017).
5.3 Purpose of the Study
The purpose of this study was to identify any association between females and males, and
whites and non-whites diagnosed with paroxysmal or persistent AF in the conversion and
sustainment of NSR using sotalol or dofetilide. This chapter contains discussion and future
research possibilities to help answer the research questions:
(R1): Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol between males and females at the 1-month, 3-month, and 6-month
post-loading interval?
(R2): Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using dofetilide between males and females at the 1-month, 3-month, and 6-month
post-loading interval?
(R3): Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using sotalol between whites and non-whites at the 1-month, 3-month, and 6month post-loading interval?
(R4): Is there an association in the conversion and sustainment of NSR from paroxysmal or
persistent AF using dofetilide between whites and non-whites at the 1-month, 3-month, and 6month post-loading interval?
The overarching hypothesis of this study was that there was no association between
males and females or whites and non-whites in the conversion and sustainment of NSR from
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paroxysmal or persistent AF using sotalol or dofetilide. The findings of this study support the
hypothesis.
5.4 Interpretation of Findings
Diversity in the participation of clinical trials is paramount in obtaining data that is
accurate to determine the efficacy and safety of drugs. Factors impacting the outcome of this
study as it relates to the effectiveness of sotalol and dofetilide may be because this cohort was
lacking in diversity related to gender and race. The catchment area for the location of this study
was urban and rural. The population consisted of 84.6% whites, 3.6% blacks, 8% Hispanics, 1%
Native American Indian/Alaskan, and 1% Asian.
5.4.1 Association in the conversion and sustainment of NSR using sotalol or dofetilide
between males and females
This study found that there was an association between males and females in the
conversion and sustainment of NSR from paroxysmal or persistent AF using sotalol or dofetilide
at the 1-month post-drug loading interval, p=.015. Upon further evaluation of the Pearson’s chiSquare and Fisher’s Exact tests of observed versus expected values, more subjects were expected
to convert to NSR using sotalol; 9.2 expected compared 1.8 observed. This could be the cause of
the statistically significant Fisher’s Exact test, however in order to obtain full clarity regarding
the significance of this result, it may be necessary to run this study on a larger and more gender
diverse sample size. Statistical significance at this stage would not necessarily affect clinical use
of these drugs. With respect to the association between males and females in the sustainment
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and conversion of NSR from paroxysmal or persistent AF using sotalol or dofetilide at the 3month and 6-month post drug-loading intervals, there was no association found, p=.444 and
p=.598 respectively. The gender demographics of this study are in line with clinical trials of
sotalol and dofetilide by the FDA in 2018. In this study, 65% of subjects were male and 35%
were female. In the clinical trial performed by the FDA in 2018 for sotalol, 64% of study
participants were male and 36% were female, while in the clinical trial for dofetilide 70% were
male and 30% were female.
5.4.2 Association in the conversion and sustainment of NSR using sotalol or dofetilide
between whites and non-whites
Race could not be accurately evaluated in this study due to the low number of non-white
participants. Of the study subjects, 80 were white and 4 were non-white. Pearson’s chi-square
analysis requires that there be at least 5 subjects in each category, however race did not meet that
requirement and thus was not analyzed. This finding is consistent with historical patterns that
show non-whites, especially blacks, are far less likely to participate in clinical trials with African
and African-American participation ranging between 1.8% and 3.5% (Knepper & McLeod,
2018).

5.4.2.1 Contributing Factors to Reduced Enrollment of Females in Clinical Trials
Many factors may impact the representation of women in clinical trials. Differential
enrollment in clinical trials based on gender has been historically documented in the literature.
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According to Ramasubbu et al, (2001) clinical trials in oncology enrolled on average 34%
women, infectious disease enrolled 39% women, cardiology enrolled 25% women, and
gastroenterology enrolled 37% women. Growth in the strength of evidence-based medicine and
the knowledge of gender-specific pharmacokinetics and pharmacodynamics raise the importance
of females being included in clinical trials. The literature points to many reasons why females
are less likely to participate or be enrolled in clinical trials. According to Ramasubbu et al.
(2001), designers of clinical research may exclude females in order to obtain a more
homogenous sample of participants with similar characteristics in an effort to improve the power
of their study, reduce variation, and in turn require a smaller sample size and reduced budgets.
Also, fear of legal liability as it pertains to teratogenicity, child-bearing ability, and pregnancy
may deter researchers from increasing the enrollment of female subjects in clinical drug trials
(Bush, 1994; Ramasubbu et al., 2001). Socioeconomic status, household responsibilities such as
childcare and work, lack of financial independence, lack of transportation, and health insurance
are also key reasons why females may choose not to participate in clinical trials (Bush, 1994;
Ramasubbu et al., 2001). Across all racial and ethnic lines in the U.S., women are paid 82 cents
for every dollar paid to men (National Partnership for Women and Families [NPWF], 2020).
According to the NPWF (2020) the median income for a woman with a full-time, year-round job
is $45,094 compared to $55,291 for a man with a full-time, year-round job; a difference of
$10,194 per year. Women of color in particular experience a much sharper gender wage gap
than their white counterparts. Latina are paid 54 cents for every dollar paid to a white, nonHispanic man, while black women are paid 62 cents, and Native American women are paid 57
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cents. The median annual income for a Latina in the U.S. who holds a full-time, year-round job
is $33,450, a black woman is $38,036, and a Native American women $34,466 while the median
annual income for a white, non-Hispanic man who holds a full-time year-round job is $61,576.
Filling the wage gap held between women, and especially women of color, compared to white
men in the U.S. could translate into more money for education, childcare, and employer-based
health insurance. Relief of these financial burdens and the ability to afford health care,
transportation, and childcare coverage could contribute to a desire for women and women of
color to participate in clinical trials.

5.5 Contributing Factors to Reduced Enrollment of Non-whites in Clinical Trials
It has long been known that African-Americans harbor deep mistrust for the health care
system compared to whites (Boulware, Cooper, Ratner, LaVeist, & Powe, 2003; LaVeist,
Nickerson, & Bowie, 2003). This mistrust has been linked to underutilization of health care
service, concern of unwitting enrollment in potentially harmful medical experiments, a
consequence of historical segregation in hospitals, and discourteous and maltreatment by hospital
personnel and health care professionals (Brandon, Isaac, & LaVeist, 2005). The legacy of the
Tuskegee Study of Untreated Syphilis in the Negro Male (The Tuskegee Study) lives on. The
Tuskegee Study was a 40 year-long study conducted by the U.S. Public Health Service that
involved the intentional deception and infection of African-American males with syphilis and the
denial of proven successful treatment. The purpose of the study was to track and document the
natural course of the disease from infection to death of the host (Brandon et al., 2005). This is
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one of the most common cited reasons for mistrust in the health care system by AfricanAmericans (Brandon et. al, 2005). Other barriers experienced by blacks related to entry into
clinical trials include economic disadvantages, lack of awareness of study programs, and
communication barriers. A study performed by Gorelick et al. (1998) attempted to determine
reasons why African-Americans 1) enrolled and remained, 2) withdrew, or 3) refused to
participate in the African-American Antiplatelet Stroke Prevention Study (AAASPS). This was a
small study performed at Rush Medical Center in Chicago with a total n=29. Participants of the
study were separated into three groups. Group 1 (patients who remained in the study, n=19);
group 2 (patients who withdrew from the study, n=4); and group 3 (patients who refused to
participate in the study, n=6). Five content area questions were posed to the participants:
1. What were your reasons for participating (voluntarily withdrawing, refusing to
participate) in the AAASPS?
2. What circumstances or events may have influenced your decision to participate
(withdraw, refuse to participate) in the AAASPS?
3. Was the information regarding the study explained to you in words or terms that you
could easily understand?
4. Did the study coordinator treat you in a respectful manner?
5. What was the opinion of your family members or friends regarding your being asked
to participate in the AAASPS?
The results of the study are as follows;
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Group 1: Patients who remained in the study
Of the 19 participants who remained in the study, 16 reported that they
participated to reduce the risk of another stroke and 6 reported their desire to find
a cure for stroke or to help others.
Group 2: Patients who withdrew from the study
Of the 4 patients who withdrew from the study, all patients cited concerns of
being subject to experimentation and the possibility of being used as a “guinea
pig.”
Group 3: Patients who refused to participate in the study
Of the 6 patients who refused to participate in the study, 2 patients cited concerns
of being used as a “guinea pig” and 3 cited the desire to keep their current
medications the same or being too busy to participate. The last participant
declined to give reason for not participating.

5.6 Strategies for Improving Enrollment of Non-whites and Females in Clinical Trials
Recruitment and retention in studies are paramount to the success of clinical trials. Due
to the deep and long history of distrust and maltreatment by the medical industry of non-whites
and in particular, blacks, this is challenging. In the study by Gorelick et al. (1998) they
identified a recruitment triangle that may help to predict a patient’s likelihood of participating in
clinical trials. This recruitment triangle consisted of three walls; the patient, the patient’s
primary care provider and other allied medical personnel, and key family and friends.
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Figure 5-1 Gorelick et. al, 1998
According to Gorelick et. al (1998), the walls of the recruitment triangle are held together by
social support, trust in the designers of research and study personnel, and education about the
nature of the research. Trust may be established by using culturally sensitive staff and improving
racial and language coherence, treating patients with respect, and clearly communicating and
educating the patients and key family and friends on the tenants of the research (Gorelick et al.,
1998). Using a low-pressured approach may also help to quell the notion of being experimented
upon by the medical community. Collapse of any of the walls of the recruitment triangle
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according to Gorelick et al. (1998) may repel blacks from contributing to clinical trials. Taking
into account this emergent recruitment triangle could help to break down barriers to enrollment.
The NIH Revitalization Act of 1993 directed the NIH to publish guidelines promoting the
inclusion of women and minorities in major federally funded clinical research (NIH, 1994). The
guidance from the NIH included guidelines for a) “the circumstances under which the inclusion
of women and minorities as study subjects in projects of clinical research is appropriate, b) the
manner in which clinical trials are required to be delegated and carried out, and c) the operation
of outreach programs. The statute states that:
•

Women are included as study subjects in each project of such research, and

•

Members of minority groups are included in such research (p. 14508)”

Revitalization of the statute adds additions stating that the “NIH must:
•

Ensure that women and members of minorities and their subpopulations are included in
all human subjects research

•

For Phase III clinical trials, ensure that women and minorities and their subpopulations
must be included such that valid analysis of differences in intervention effect can be
accomplished

•

Not allow cost as an acceptable reason for excluding these groups and,

•

Initiate programs and support for outreach efforts to recruit these groups into clinical
studies (p. 14508).”

The revised guidelines also required women of childbearing ability to be included in all phases
of clinic trials for drug development (NIH, 2016). The NIH has gone further amending the
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guidelines in 2001 to require the reporting on gender, race and ethnicity in federally funded
clinical trials (Bowleg, 2012).
Understanding and addressing concerns and questions of females and minorities with
understandable and sensitive feedback in the research process is paramount if the goal is to
obtain and keep them enrolled in clinical trials (Martin, Negron, Balbierz, Bickell & Howell,
2013). In order to achieve truly generalizable data from clinical trials efforts must be taken to
include non-whites and minorities in clinical trials.

5.7 Limitations
The results of this study must be interpreted within the context of its limitations. This
study was performed at one institution with a catchment area that was >80% white. The study
subjects were predominantly white and male. This makes generalizability to non-whites and
females and then extrapolation of data results to these populations unreliable. As the catchment
area was predominantly white, race was not able to be included in statistical analysis leaving data
for non-whites lacking in this study. With respect to race, for the study subjects, it was selfdocumented leaving room for error or personal preference that could not be accounted for during
the research process. As mentioned previously, AF can co-occur with other dysrhythmias
impacting the efficacy of medical and procedural treatment. This study did not take into account
the fact that other dysrhythmias may have impacted the outcome of the patient’s ECGs. It is also
noteworthy that some patients in the study may have required additional treatment to sustain
NSR in addition to sotalol and dofetilide. Additional and alternative treatments may have an
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impact on the efficacy of the two drugs that was not studied in this research. Comorbidities like
HTN, OSA, CAD, and valvular heart disease may cause, exacerbate, or reduce the efficacy of
treatment of AF (January et al., 2014). Many of the study subjects were diagnosed with one or
more of these comorbidities which may have had an impact on the outcome. Behavioral
characteristics also impact the outcome of treatment of AF. Medication non-compliance,
cigarette smoking, excessive caffeine intake, alcohol use or use disorder, illicit drug use, having
a sedentary lifestyle or excessive exercise can have an impact on treatment outcomes (January et
al., 2014). Although patients are counseled to avoid these behaviors, it was not possible to insure
total adherence. With respect to ECGs, it is noteworthy that during this study, they were only
evaluated at the 1-month, 3-month, and 6-month post-drug loading interval. This gives a brief
view of the patient’s heart rhythm while they are in a controlled environment. These ECGs do
not represent the patient’s heart rhythm outside of this environment rendering complete
assessment impossible. It is very likely that the patients may have had AF or other dysrhythmias
that were not documented during the course of this study.

5.8 Recommendations for Future Research
This study brings to light the importance of including females and non-whites in clinical
trials. In order to improve upon this research, including multiple institutions with more diverse
catchment areas and a larger sample size may help to achieve generalizable results and include
accurate data specifically pertaining to females and non-whites. As comorbidities do play a role
in the outcome of treatment of AF, including those other medical problems as variables will
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assist the clinical provider in determining the potential efficacy in treatment using sotalol or
dofetilide. Along with the aforementioned comorbidities being represented in future studies,
including other dysrhythmias will also provide valuable information related to how they affect
the outcome of treatment of AF with sotalol or dofetilide. Lastly, AF may cause no symptoms or
severely debilitate patients and negatively affect their quality of life (January et al., 2014).
Future studies may be done to determine the level of improvement in a patient’s quality of life
and their rate of conversion to NSR.
In summary, these findings represent implications for future research and contribute to a
larger body of work highlighting the need to include females and non-whites in clinical trials.
More research is needed in an effort to obtain safety and efficacy information of sotalol,
dofetilide, and other approved drugs for underrepresented populations.
5.9 Conclusion
Clinical research can potentially advance the health of all individuals in society, but for that
to happen, clinical trials must become more diverse. This is not only a matter of reducing health
disparities based on gender, race, and ethnicity, but of positively impacting social justice and
strengthening science and society (Perez-Stable, 2018). Intersectionality, as a means to shed
light on the impact discriminating social identities have on health care and other areas of
importance, does well to reveal the breaches in clinical research that lead to inaccurate and, at
times, dangerous data for subpopulations such as females and non-whites. This theoretical
framework provides science and other industries with valuable foresight and historical insight
that has the potential to identify and rectify the privilege and oppression woven into American
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society. This research holds true to inequities in clinical trials across the country and abroad in
its representation of predominantly white males. As no statistical significance was found in the
analysis of the data, the overarching historical problem remained; a lack of females and nonwhite participants. It is noteworthy that participation of females and non-whites does not
squarely land at the feet of motivation of these two groups. What must also be considered are
access to clinical trials, health insurance coverage, wage gaps, historical mistrust, education, and
communication. These areas must be addressed and remedied if females and non-whites are to
be better represented in clinical trials.
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